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 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with no 
effective therapies. While abundant genetic, histological, and experimental evidence links 
the beta-amyloid (Aβ) peptide to disease onset and progression, the mechanisms behind 
neuronal dysfunction in AD are not completely understood.  
It is now clear that AD is a complex, multifactorial disease characterized by vascular 
dysfunction, prothrombotic state, and inflammation, but whether these conditions are a 
cause or consequence of disease is debated. Prothrombotic and inflammatory states can 
contribute to alterations in cerebral blood flow resulting in hypoperfusion. Since neuronal 
function is dependent on an uninterrupted blood supply sustained by a healthy vasculature, 
agents capable of eliciting thrombosis and/or inflammation could play a key role in AD onset 
and progression.  
The contact activation system, initiated by activation of the plasma protein FXII, is 
capable of launching both thrombotic and inflammatory pathways. I investigated whether Aβ 
could directly induce these pathways by interacting with FXII in vitro, in AD mouse models, 
and in AD patients. A prothrombotic state may also result from reduced clot degradation, as 
seen in mouse models of AD. I therefore investigated the mechanism by which clots formed 
in the presence of Aβ are structurally altered and resistant to degradation. 
 
I established the ability of Aβ to initiate prothrombotic and inflammatory processes via 
activation of the FXII-driven contact system, and provided evidence for these processes in 
AD patients and mouse models. I also defined the regions involved in Aβ-fibrinogen binding 
and elucidated the mechanism by which this interaction results in delayed fibrinolysis. My 
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CHAPTER 1. INTRODUCTION 
1.1. Alzheimer’s disease: demographic and clinical features  
Alzheimer’s disease (AD) is the most common type of dementia, affecting over 5.2 
million Americans and 26 million people worldwide. Age is the greatest risk factor: one in 
nine people age 65 and over (11%) and one third of those age 85 and over (32%) have AD1. 
As the global population achieves higher longevity due to advances in medicine, the 
prevalence of AD will continue to increase. By 2050, the number of Americans age 65 and 
over with AD is projected to triple to 13.8 million if treatments to prevent or slow disease are 
not developed. The disease is and will continue to be an immense financial burden: the cost 
of care for individuals with AD is projected to increase from $203 billion in 2013 to $1.2 
trillion in 20501.   
At its earliest stages, AD is clinically characterized by deficits in the ability to learn and 
remember new information. Symptoms progress to include impairment of semantic memory 
(concept-based knowledge), executive function (problem solving, planning, and execution), 
and visuospatial skills2. In late stages of disease, brain regions responsible for controlling 
life-sustaining functions become affected, leading to death. Neuropathologically, AD is 
characterized by the accumulation of the peptide beta-amyloid (Aβ) in the brain parenchyma 
(plaques)3 and by the intraneuronal accumulation of filamentous hyperphosphorylated tau 
protein (tangles)4. In addition to these diagnostic criteria, other histological changes found in 
AD brains include vascular pathology, neuroinflammation, dystrophic neurites, and brain 
atrophy. The etiology of AD is complex and still poorly defined. Despite decades of research, 
the initiating event(s) behind neuronal dysfunction remain unclear. Many theories have 
emerged from the study of the neuropathological hallmarks described above, with most 
identifying the Aβ peptide as a critical player in AD pathogenesis. 
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1.2. AD etiology: Aβ hypothesis  
Aβ is proteolytically derived from the ubiquitously expressed transmembrane protein 
amyloid precursor protein (APP). Cleavage of APP by the aspartyl protease β-secretase 
creates the N-terminus of the Aβ peptide. Release of Aβ is mediated by the γ-secretase 
catalytic component presenilin, which cleaves the remaining portion of APP at one of 
several sites, creating a 39 to 43 amino acid Aβ peptide (Figure 1.1). The most common 
form of Aβ generated is 40 amino acids long (Aβ40), with the 42 amino acid peptide (Aβ42) 
considered to be the more pathogenic form5.  
Normally, the generation of Aβ in the brain is balanced by its clearance, which is 
mediated by proteolytic degradation6, cell-mediated clearance7,8, perivascular drainage9, and 
transport across the blood-brain barrier (BBB) into the circulation10. A rise in Aβ 
concentration leads to the formation of soluble Aβ oligomers, with subsequent fibrillization 
and deposition in the form of plaques11 (Figure 1.1). Mutations in genes resulting in 
increased production of Aβ or in the production of Aβ with decreased potential for clearance 
are associated with elevated AD risk, providing a genetic link between Aβ and AD. For 
example, mutations in APP, presenilin 1, or presenilin 2 induce altered Aβ production and 
are responsible for an early onset, autosomal dominant form of the disease12. Furthermore, 
triplication of the APP-bearing chromosome 21 in Down Syndrome results in increased Aβ 







Figure 1.1. Production of Aβ from APP. The ubiquitously expressed transmembrane 
protein APP undergoes processing by β- and γ-secretases to release C-terminal soluble 
APP (sAPP), the Aβ peptide, and an N-terminal intracellular domain (ICD). Aβ can self-





In contrast to these early-onset AD cases, it is thought that the vast majority of sporadic 
(late-onset) AD stems from defective Aβ clearance and not increased Aβ production14-16. 
Indeed, the strongest genetic risk factor for late-onset AD is apolipoprotein E (APOE) 
genotype, with individuals carrying the APOE ε4 allele being at an increased risk of AD 
compared to ε3 and ε2 carriers17,18. While the role of ApoE in AD is complex and not fully 
understood, one aspect of its function is that it disrupts the transport of parenchymal Aβ 
across the BBB by LRP1 receptors, with the ε4 isoform disrupting the efficiency of Aβ 
clearance more than ε3 and ε219.  
Correlations between Aβ accumulation and AD at both a histological and genetic level 
support the “Aβ hypothesis of AD,” which states that a chronic imbalance in production 
versus clearance of Aβ leads to its gradual accumulation in the brain, which over the many 
years of AD development results in pathological changes characteristic of AD, including 
microgliosis, astrocytosis, neuronal dysfunction, and cognitive impairment11. The idea that 
Aβ accumulation can result in AD-related pathological and clinical changes is supported by 
experimental evidence of Aβ-mediated toxicity. Aβ oligomers induce neuronal mitochondrial 
dysfunction20, synaptic dysfunction21-23, and directly promote neuronal death21. Aβ deposits 
trigger microglial and astrocytic activation, which can contribute to neuronal dysfunction 
through inflammatory processes24. Thus, neuronal dysfunction due to Aβ’s direct or glial cell-
mediated toxicity can cause cognitive decline. However, Aβ deposits are also found in 
neurologically normal individuals25-27, indicating that Aβ does not always induce neurotoxicity, 
and suggesting that other factors contribute to AD onset.  
1.3. AD etiology: vascular hypothesis  
A healthy brain vasculature is critical for neuronal viability and cognitive function. 
Oxygen and nutrients are supplied to the brain by arteries, which branch into arterioles and 
finally into capillaries. Capillary walls mediate exchange of substances between the 
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circulation and brain parenchyma and constitute the BBB. Brain function is dependent on a 
tightly regulated BBB and on consistent cerebral blood flow (CBF)28, which can be 
dramatically affected by very small changes in cerebral vessel biology and structure29. While 
cerebrovascular dysfunction has traditionally been thought to cause a distinct disease called 
vascular dementia, a large body of evidence now indicates that significant overlap exists 
between vascular dementia and AD, blurring this distinction30. Indeed, cerebrovascular 
pathology is present in virtually all AD patient brains upon autopsy31-36 and BBB dysfunction 
is increasingly recognized as an important aspect of AD pathology28,37-39, but whether these 
changes play a causal role in AD or are simply co-morbidities is still debated.  
The idea that vascular pathologies may be causative in AD stems from evidence that 
they precede AD development. Conditions associated with vascular disease such as 
diabetes, hypertension, hypercholesterolemia, atherosclerosis, silent brain infarcts, and 
white matter lesions increase the risk of developing AD40-44, with nearly all of them present 
not only at AD onset but also decades before any loss of cognitive function develops41. 
Many of them can compromise CBF and induce brain hypoperfusion29, which are observed 
early in the course of AD28,45,46. Disturbances in CBF and brain perfusion can lead to BBB 
dysfunction, dysregulation of nutrient transport, neuronal dysfunction, and eventually 
cognitive decline41,47. Hypoxia and energy deficits resulting from hypoperfusion can 
accelerate Aβ deposition, increase tau hyperphosphorylation, impair BBB functions, 
precipitate neuronal loss, and produce cognitive dysfunction46,48-50, all of which are 
pathological hallmarks of AD. Even a relatively mild restriction in blood supply to brain tissue 
causes long-term dysfunction of synaptic transmission51, underscoring the idea that small 
deficits in oxygen and nutrient supply can over time have significant effects.  
The presence of morphological abnormalities in the AD brain vasculature, the 
epidemiologic connections between vascular disease risk factors and AD risk, and the 
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potential mechanistic connections between vascular and neuronal dysfunction provide a 
basis for an alternative theory known as the “vascular hypothesis of AD,” which states that 
deficiencies in vascular function and CBF gradually lead to the pathological and molecular 
characteristics of the disease29,41. Thus, the “Aβ hypothesis” identifies Aβ as a primary driver 
in AD, while the “vascular hypothesis” identifies vascular dysfunction as a cause of AD 
neuropathology and symptoms. But what exactly causes vascular dysfunction in individuals 
at risk for AD?  
In this thesis, I would like to propose that Aβ itself could drive the vascular changes that 
may lead to AD onset and progression, providing a link between the Aβ and vascular 
hypotheses. Exploring this connection requires the introduction of two additional pathologic 
states associated with AD. 
1.4. Prothrombotic state in AD  
In keeping with a link between AD and vascular dysfunction, accumulating evidence 
suggests that AD patients and mouse models exhibit a prothrombotic or hypercoagulable 
state, defined as an increased tendency toward clot formation. Clot formation is mediated by 
activated platelets and the coagulation cascade, which involves the sequential activation of 
a series of factors resulting in the production of thrombin. AD patients have elevated plasma 
levels of activated Factor VII, prothrombin fragment 1+2, von Willebrand Factor52,53, and 
activated platelets54,55, all of which reflect or promote increased thrombin generation. The 
existence of a prothrombotic state in AD would be expected to increase the incidence 
thrombotic events. Indeed, AD patients are at a higher risk for microinfarcts56,57 and stroke58 
compared to non-demented controls, microinfarct number correlates with cognitive decline 57, 
and AD mouse models have a greater propensity to form thrombi59,60.   
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An important question is whether the prothrombotic state in AD patients is a cause or 
consequence of disease. Evidence for a causative role comes from epidemiological studies 
suggesting that prothrombotic states may contribute to disease onset and progression. 
Older adults with increased D-dimer and prothrombin fragment 1+2 levels, both markers of 
increased thrombin generation, are at higher risk for cognitive decline61, and increased 
levels of coated platelets (a highly pro-coagulant subset of activated platelets62) correlate 
with future AD severity63 and progression from MCI to AD64. Conditions characterized by 
hypercoagulability such as factor V Leiden (a prothrombotic mutation in factor V)65, elevated 
plasma homocysteine levels66-68, elevated plasma fibrinogen levels69, silent brain infarcts40, 
and stroke70-72 place individuals at increased risk for AD. The hypothesis that a 
prothrombotic state contributes to AD is also supported by improvements in AD pathology 
and memory in AD patients73-75 and mouse models76,77 following treatment with 
anticoagulants.  
1.5. Proinflammatory state in AD  
Inflammation is a well-established component of AD pathology supported by proteomic, 
histological, genetic, and epidemiological evidence24,78. Inflammation in the AD brain 
parenchyma is characterized by increased levels of activated microglia and astrocytes (the 
cellular mediators of inflammation in the brain) as well as by increased levels of complement 
system components and cytokines24. Chronic activation of astrocytes diminishes their 
capacity to support neuronal health79,80, and the release of proinflammatory molecules from 
chronically activated microglia and astrocytes combined with chronic complement activation 
can directly induce neuronal toxicity81. Inflammation in AD is observed not only in the brain 
parenchyma, but also in the periphery: AD plasma and serum have elevated levels of 
circulating proinflammatory cytokines, chemokines24,78, and acute phase proteins, and AD 
blood cells produce increased levels of cytokines78,82. The idea that peripheral inflammation 
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can contribute to and/or reflect neuroinflammation and neuropathology is supported by 
studies in AD patients and mouse models demonstrating that elevated circulating levels of 
proinflammatory molecules correlate with increased microglial activation, neuronal loss, and 
cognitive decline78. 
Whether inflammation is a primary driver of AD, a toxic consequence of other AD-related 
processes, or a protective response delaying AD onset is debated83. However, several lines 
of evidence support a role for inflammation in driving AD onset and progression. Mouse 
models of AD show microglial activation prior to Aβ plaque deposition84,85, microglial 
activation is seen in prodromal AD86,87, and is increased in early to moderate AD compared 
to controls88,89. Further support comes from studies showing that peripheral markers of 
inflammation increase the risk of AD90, that incidence of systemic infections increase the risk 
of dementia91, and that cognitive impairment in AD individuals is exacerbated during and 
after systemic infection92. Finally, numerous epidemiological studies show that long-term 
nonsteroidal anti-inflammatory drug use reduces AD risk24.  
1.6. Contribution of prothrombotic and inflammatory states to vascular dysfunction 
 Thrombosis and inflammation can contribute to vascular dysfunction through multiple 
mechanisms. Thrombus formation in arterioles decreases CBF in downstream capillaries93, 
while thrombosis in venules disrupts local CBF and decreases CBF in upstream capillaries94. 
Chronically decreased CBF can lead to vascular endothelial cell remodeling, endothelial cell 
death95, and capillary collapse47. Thrombin itself can mediate endothelial cell permeability in 
vitro96-98 and precipitate BBB dysfunction and breakdown in vivo99,100. BBB dysfunction 
results in leakage of plasma proteins into the brain parenchyma, leading to vessel wall 
thickening and subsequent functional deterioration101,102. Furthermore, thrombin binding to 
protease activated receptors on endothelial cells promotes the release of proinflammatory 
cytokines103,104, thereby contributing to inflammatory processes.  
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Inflammation-induced vascular dysfunction may stem from changes in the ability of 
chronically activated astrocytes to control vascular tone and BBB function79,80 as well as 
from a proinflammatory state in the periphery. Circulating proinflammatory molecules such 
as cytokines, activated complement components, and bradykinin can modify vascular 
endothelial cell function and increase BBB permeability105-109.  Indeed, mouse models with 
systemic inflammation have increased susceptibility to BBB permeability110-112. The ability of 
inflammatory processes to elicit clinically-relevant vascular dysfunction is illustrated by the 
etiology of vascular disease in humans. Inflammation-induced endothelial activation and 
leakage of blood components through a compromised endothelium can lead to chronic 
vascular diseases such as atherosclerosis107,113 and cerebral small vessel disease114,115, 
both characterized by vessel narrowing and stiffness107,115,116.  
Thus, changes to vascular biology, structure, and permeability induced by thrombotic 
and inflammatory mediators could be a key mechanism behind the vascular dysfunction, 
BBB dysregulation, and CBF reduction implicated in the initiation and/or progression of AD. 
1.7. A possible role for Aβ in thrombosis and inflammation  
If dysregulated coagulation and inflammation play a role in inducing and/or exacerbating 
vascular pathology, pathways capable of triggering these processes are of great interest to 
AD etiology. The contact activation system, which can launch both prothrombotic and 
proinflammatory pathways, is initiated when the plasma protein factor XII (FXII) is exposed 
to negatively charged surfaces (contact activation)117. Contact activated FXII (FXIIa) cleaves 
plasma prekallikrein to generate plasma kallikrein, which in turn cleaves high molecular 
weight kininogen (HK) to release the proinflammatory mediator bradykinin (Figure 1.2, 
kallikrein-kinin system). In addition to cleaving prekallikrein, FXIIa also activates factor XI 
(FXI) in the intrinsic coagulation cascade leading to thrombin generation, the conversion of 
fibrinogen to fibrin, and clot formation (Figure 1.2, intrinsic coagulation pathway). Activation 
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of the contact system also produces numerous proteases (including FXIIa, kallikrein, FXIa, 
and thrombin) capable of complement system activation118-120 (Figure 1.2). In AD, a possible 
surface for FXII activation could be Aβ, which has been shown to stimulate FXII-dependent 
plasma kallikrein activity121,122 and HK cleavage121,123 in vitro.  
Thrombotic potential is mediated not only by agents capable of modulating the 
coagulation cascade, but also by factors affecting the physical and biochemical stability of 
the forming fibrin clot, which is very sensitive to the conditions under which it is formed124. In 
this regard, binding of Aβ to fibrinogen125 in the forming clot may further promote thrombosis 
by inducing changes in clot structure and stability59.  
The potential for interactions between Aβ and FXII and/or fibrinogen in vivo is supported 
by studies placing Aβ at sites of possible thrombosis and inflammation at increased 
concentrations. This includes locally elevated levels of Aβ at the luminal side of cerebral 
capillary walls, where Aβ enters the blood through the BBB10, secretion of Aβ by activated 
platelets126, and Aβ accumulation in atherosclerotic lesions127. Taken together, accumulating 
evidence supports the hypothesis that Aβ may act as both an initiator of coagulation and 















Figure 1.2. The contact activation system. Contact between FXII and negatively charged 
surfaces produces activated FXII (FXIIa), which can lead to activation of the intrinsic 
coagulation pathway (blue panel) and the plasma kallikrein-kinin system (green panel). 
Activation of FXI to FXIa triggers a cascade of proteolytic reactions ultimately resulting in the 
formation of thrombin, which mediates clot formation. Plasma kallikrein (PK) generated from 
FXIIa-mediated plasma prekallikrein (PPK) activation further activates FXII (feedback 
activation) and cleaves high molecular weight kininogen (HK), which releases bradykinin. 





AD is an enormous and growing public health problem, due in large part to the fact that 
there are no effective therapies. Major roadblocks to the treatment of AD are the lack of 
adequate diagnostic tools and the absence of viable therapeutic targets, both stemming 
from an incomplete understanding of the mechanistic basis of AD etiology and progression.  
The induction of prothrombotic and inflammatory states by Aβ could explain the 
epidemiological associations between AD, thrombosis, and inflammation. At the same time, 
Aβ-mediated activation of inflammatory and prothrombotic processes could be the missing 
link connecting the Aβ hypothesis with the vascular hypothesis of AD. Evaluation of the 
possibility that Aβ could act as a trigger for thrombosis and inflammation by interacting with 
plasma proteins FXII and fibrinogen is the focus of the work presented in this thesis. A 
detailed understanding of these interactions may reveal new pathological mechanisms, 





CHAPTER 2. MATERIALS AND METHODS 
2.1. Identification of fibrinogen regions that interact with Aβ 
Plasminogen was purified from human plasma (NY Blood Center) using lysine-
sepharose as described128, and co-purifying plasmin was inactivated with 10 mM diisopropyl 
fluorophosphate (Sigma). Human plasminogen-free fibrinogen (Calbiochem; 5 mg/ml in 50 
mM Tris, pH 7.4, 150 mM NaCl, 5 mM iodoacetamide) was incubated with 0.6 µM 
plasminogen and 0.37 µM tPA (generously provided by Genentech) overnight at 37°C to 
generate small fibrinogen degradation products (FDPs) or with 140 nM plasminogen and 20 
nM tPA for 6 hours (hrs) at 37°C to generate large FDPs. Digestions were stopped with 
aprotinin (Sigma). FDPs (500 µl) were incubated for 3 hrs at room temperature (RT) with 
synthetic N-terminally biotinylated Aβ42 (Anaspec; 200 nM or 2 µM final concentration) in 
phosphate buffered saline (PBS) adjusted to contain 500 mM NaCl, 0.01% NP-40 and 
protease inhibitor cocktail (Roche), the Aβ-interacting peptides pulled down with 
streptavidin-sepharose beads (Invitrogen) for 1 hr at RT, and the peptides eluted with 
sample loading buffer and analyzed by SDS-PAGE on a 4-20% gradient gel (Life Sciences) 
with colloidal blue staining (Invitrogen). Incubations that did not contain biotinylated Aβ42 
served as a control for non-specific binding to the streptavidin-sepharose beads.  
Mass spectroscopy was performed by the Rockefeller University Proteomics Resource 
Center as follows: protein gel bands were excised from the SDS-PAGE. Gel bands were 
reduced with 10 mM dithiothreitol (DTT) and alkylated with 55 mM iodoacetamide, 
then digested with Sequence Grade Modified Trypsin (Promega) in ammonium bicarbonate 
buffer at 37°C overnight. Digestion products were extracted twice with 0.1% trifluoroacetic 
acid, 50% acetonitrile, and 1.0% trifluoroacetic acid. The extracted mixture was dried by 
Speed-Vac and re-dissolved in 10 ml 0.1% trifluoroacetic acid. For LC-MS/MS analysis, the 
Dionex U3000 capillary/nano-HPLC system directly interfaced with the LTQ-Obritrap mass 
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spectrometer (Thermo Fisher), which was operated in the data-dependent acquisition mode 
using Xcalibur 2.0.7 software. The MS/MS scans from each LC-MS/MS run were converted 
from the .RAW file format to .DTA files using Bioworks 3.3.1 software. DTA files were 
analyzed using the MASCOT software search algorithm. 
2.2. MALDI-TOF mass spectrometry and Edman sequencing   
MALDI-TOF mass spectrometry and Edman sequencing were performed by the 
Rockefeller University Proteomics Resource Center. Coomassie blue-stained bands were 
excised from SDS-polyacrylamide, destained with 200 mM ammonium bicarbonate in 50% 
acetonitrile, and treated with 10 mM DTT in 0.1 M ammonium bicarbonate for protein 
reduction. Free cysteine residues were alkylated with freshly made 55 mM iodoacetamide in 
0.1 M ammonium bicarbonate. Tryptic digestion was performed with 25 ng/µl Sequence 
Grade Modified Trypsin (Promega) in ammonium bicarbonate buffer for 16 hrs at 30°C with 
agitation. Digestion products were cleaned and concentrated using micro-C18 ZipTip 
(Millipore), mixed with 0.5 µl of 10 mg/ml α-cyano-4-hydroxysuccinnamic acid in 50% 
acetonitrile, 0.1% (v/v) TFA, and applied onto a MALDI plate. MALDI mass spectra were 
recorded with a PerSeptive Voyager-DE STR MALDI time-of-flight mass spectrometer 
operated in the reflectron mode. The mass measurement accuracy with internal calibration 
was, in general, better than 100 ppm. The measured peptide masses were used for 
database searching with ProFound algorithm. Edman sequencing was performed using an 
Applied Biosystems Procise sequencer.   
2.3. Pulldown assay between Aβ and 49 amino acid fibrinogen β-chain fragment 
A 49 amino acid fragment corresponding to fibrinogen β-chain residues 366-414 
(TMTIHNGMFFSTYDRDNDGWLTSDPRKQCSKEDGGGWWYNRCHAANPNGR) was 
synthesized at Rockefeller University’s Proteomics Resource Center. N-terminally 
biotinylated Aβ42 (200 nM) or vehicle was incubated with the 49-mer (1 µM) in PBS 
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containing 0.01% NP-40 and protease inhibitor cocktail (Roche) for 2 hrs at RT. Biotinylated 
Aβ42 and its binding partners were pulled down using streptavidin-sepharose beads for 1 hr 
at RT, washed, and eluted with sample buffer. Eluates were analyzed by SDS-PAGE on a 4-
20% gradient gel followed by silver staining (Thermo Scientific).  
2.4. Preparation and purification of fibrinogen fragment D 
Fibrinogen fragment D was prepared and purified as described in 129. Briefly, 
plasminogen-free human fibrinogen (Calbiochem) was reconstituted in 50 mM Imidazole, 5 
mM CaCl2, 150 mM NaCl, pH 7.4 and treated with 5 mM iodoacetamide (Sigma). Fibrinogen 
was digested with 0.01 mg TPCK trypsin (Pierce) per 1 mg fibrinogen for 4 hrs at 22°C. 
Digestion was stopped with soybean trypsin inhibitor (0.03 mg soybean trypsin inhibitor per 
1 mg fibrinogen). Fragment D was affinity purified using the GPRPC peptide (prepared at 
the Rockefeller University Proteomics Resource Center) covalently immobilized on a 
SulfoLink Coupling Resin column (Thermo Scientific). The column was equilibrated with 50 
mM imidazole, 5 mM CaCl2, 150 mM NaCl pH 7.0, and fibrinogen degradation products 
were applied to the column and allowed to incubate for 15 minutes (min) with end-over-end 
rotation. The column was washed with 50 mM imidazole, 1 M NaBr, pH 7.2 and fragment D 
eluted with 50 mM NaAc, 1 M NaBr, pH 5.3. Eluted fragment D was neutralized with 2 M Tris, 
pH 8.0 and dialyzed into PBS. Affinity-purified fragment D was subjected to another step of 
fast protein liquid chromatography (FPLC) purification using a Superose 12 gel filtration 
column on an AKTA protein purification system (GE Healthcare), eluting in 50 mM Tris pH 
7.0. The purity of the fragment D preparation was confirmed by SDS-PAGE followed by 
colloidal blue staining. 
2.5. Western blot analysis 
Non-reduced or reduced samples were subjected to SDS-PAGE on 10% or 4-20% 
gradient gels, transferred to polyvinylidene fluoride (PVDF) membranes (Millipore), and 
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incubated in blocking buffer (5% milk in PBS containing 0.1% Tween-20 (PBS-T)) for 30 min 
at RT. Membranes were incubated with primary antibody diluted in blocking buffer for 2 hrs 
at RT or overnight at 4°C. After washing with PBS-T, membranes were incubated with HRP-
conjugated secondary antibodies in blocking buffer for 1 hr at RT. After washing, 
membranes were incubated with chemiluminescent substrate (Perkin-Elmer or GE) and 
exposed to film (Ewen-Parker). Blots were stripped with stripping buffer (Thermo Scientific) 
when analysis with multiple antibodies was necessary. For quantification, film exposures 
were chosen such that all bands were below saturation level, and images were imported into 
ImageJ software130. The density of each band was measured by selecting a rectangular 
area slightly larger than the band (the area of the rectangle was constant for all bands 
corresponding to the same protein) and measuring mean pixel intensity for that area. 
Rectangles of identical size were then used to measure background pixel intensity directly 
above or below each band, which was then subtracted from the corresponding band’s pixel 
intensity.  
2.6. Pulldown assay between Aβ or Aβ fragments and fibrinogen fragment D 
Synthetic N-terminally biotinylated Aβ fragments 1-16, 15-25, 17-40, 22-41, 1-40, and 1-
42 (200 nM, Anaspec) were incubated with fibrinogen (1 nM) or fibrinogen fragment D (200 
nM) for 1 hr at RT in 50 mM Tris pH 8.0 containing 500 mM NaCl, 0.01% NP-40 and 
protease inhibitor cocktail. Streptavidin beads were added for 30 min, and elution was 
conducted as described above and analyzed by Western blot using a polyclonal antibody 
against fibrinogen (Dako). For some experiments, biotinylated Aβ42 (200 nM) was incubated 
with varying concentrations of non-biotinylated Aβ17-42 and a pulldown assay performed as 
described above. In some experiments, fibrinogen fragment D was biotinylated using Sulfo-
NHS-biotin (Pierce). Pulldown assays were performed with biotinylated fragment D (200 nM) 
and Aβ42 I31P or Aβ42 G37D (1 µM) in 50 mM Tris pH 7.4 containing 150 mM NaCl, 0.01% 
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NP-40, protease inhibitor cocktail, and 0.1% bovine serum albumin (BSA) as described 
above. Western blots were probed with antibodies against fibrinogen (Dako) and Aβ (3D6, 
Elan).  
2.7. Crystallization of fibrinogen fragment D-Aβ42 complex 
Fragment D crystals were obtained with the assistance of the Rockefeller University 
Structural Biology Resource Center as described in 129. Briefly, crystals were obtained by 
sitting drop vapor diffusion at RT from 50 mM Tris, pH 8.5, 70 mM CaCl2, 2 mM sodium 
azide, 12-17% polyethylene glycol (PEG) 3,350 in drops of 10-20 µl, with fragment D 
(prepared as described in Methods 2.5) at 15 mg/ml. Aβ42, Aβ42 G37D, Aβ42 I31P, and 
Hylite fluor 555-Aβ42 (all from Anaspec) were reconstituted to 0.7-1.5 mg/ml in 50 mM Tris, 
pH 8.5 with 0.12% NH4OH, then diluted 2-fold in 2X reservoir buffer (50 mM Tris pH 8.5, 4 
mM sodium azide, 140 mM CaCl2, 34% PEG 3,350) to yield Aβ peptides in 1X reservoir 
buffer. Fragment D crystals were then soaked in the various Aβ solutions (containing an 
excess of Aβ over fragment D) for two weeks at RT, frozen in the N2 cryostream in reservoir 
buffer without cryoprotection, and diffracted to 3.3 Å (for Aβ42-soaked crystals) at the 
National Synchrotron Light Source, Brookhaven National Laboratory (Beam line X25, 
wavelength = 1.1 Å). We also obtained data to 2.9 Å for crystals not subjected to soaking 
(native crystals). Data reduction was performed using HKL2000 software131. Molecular 
replacement was performed with PHENIX software (PHENIX-dev-1555) using the PDB entry 
1FZA for fragment D132, resulting in successful determination of the phases and coordinates 
of fragment D atoms. Refinement was performed with PHENIX software133.  
2.8. Preparation of Aβ and control peptides for fibrinolysis experiments 
Aβ42 (Anaspec) was reconstituted to 1 mg/ml in 50 mM Tris pH 7.4, 0.1% NH4OH and 
stored at -80°C. Prior to use, Aβ42 was incubated at 37°C with shaking for 12 hrs to 
generate a range of oligomeric species. Insoluble Aβ42 was removed by centrifugation at 
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12,000 x g for 10 min134. The concentration of soluble Aβ42 was verified via bicinchoninic 
acid assay (BCA), and a representative transmission electron microscope (TEM) image of 
the Aβ42 preparation used is shown in Figure 3.5A. HiLyte Fluor 555-Aβ42 and HiLyte Fluor 
555-Aβ(1-9) (Anaspec) were reconstituted to 0.5 mg/ml in the same buffer and not 
incubated prior to use unless otherwise indicated.  
Amylin (Anaspec) was reconstituted to 2 mg/ml in dimethyl sulfoxide (DMSO). Prior to 
use, amylin was diluted to 0.2 mg/ml with 50 mM Tris pH 7.4 (10% DMSO final 
concentration) and incubated for 24 hrs at 37°C with shaking. Presence of amyloid fibrils 
was confirmed by TEM (Figure 3.5G) and Thioflavin T fluorescence (not shown).  
2.9. Transmission Electron Microscopy 
Samples were diluted to 0.1 mg/ml, applied to glow discharged CF200-Cu grids 
(Electron Microscopy Sciences), washed three times with ultrapure water (UV-treated with a 
Millipore system), and negatively stained with 2% uranyl acetate. Images were acquired 
using a JEOL JEM 100CX Transmission Microscope at the Rockefeller University Electron 
Microscopy Resource Center.  
2.10. Preparation of fibrin monolayers  
Fibrin monolayers were prepared in Fisherbrand High Binding 96-well plates (Fisher 
Scientific) as described135,136. Wells were treated with 2.5% glutaraldehyde in 0.1 M sodium 
bicarbonate buffer pH 9.5 for 2 hrs at 37°C. After washing with ultrapure water, 0.3 µM 
fibrinogen in PBS + 1 mM CaCl2 (60 µl) was applied for 18 hrs at 4°C. Wells were washed 3 
times with PBS, and free aldehyde groups were neutralized with 100 µl 0.3 M ethanolamine 
pH 7.4 during a 1 hr incubation at RT. Wells were washed 3 times with PBS, and 
immobilized fibrinogen was converted to fibrin with 1 U/ml thrombin (Sigma) in PBS (60 µl) 
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for 1 hr at 37°C. Fibrin-bound thrombin was eluted with 0.5 M NaCl, and fibrin monolayers 
were stored at 4°C in PBS + 20 mM lysine.  
2.11. Clot turbidity analysis 
Assays were performed at RT in Fisherbrand High Binding 96-well plates in triplicate 
using a Molecular Devices Spectramax Plus384 reader. Clot formation was detected as a 
change in absorbance at 350 nm, with readings taken every 30 seconds (s). For clot 
formation and lysis, fibrinogen (1.5 µM) with or without Aβ42 (3 µM) was mixed with 
plasminogen (125 nM-300 nM), α-thrombin (Sigma; 0.5 U/ml), tPA (0.15 nM-15 nM), and 
CaCl2 (5 mM) in 20 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid) 
buffer (pH 7.4) with 140 mM NaCl, in a volume of 150 µl. The absence of plasmin activity in 
the plasminogen preparation was confirmed by chromogenic substrate assay (not shown). 
In some experiments, Aβ42 I31P and 555-Hylite Fluor Aβ42 and 555 Hylite Fluor Aβ(1-9) 
were used.  
For lysis of pre-formed clots, fibrinogen (2.2 µM) with or without Aβ42 (5 µM) was mixed 
with plasminogen (125 nM), thrombin (0.5 U/ml), and CaCl2 (5 mM) in 20 mM HEPES buffer 
(pH 7.4) with 140 mM NaCl, in a volume of 100 µM. Clots were incubated at 37°C for 1 hr, 
then overlaid with a 100 µl solution containing 10-50 nM tPA, 250 nM plasmin (Sigma) or 1 
µM bovine TPCK trypsin (Thermo Scientific). Clots overlaid with plasmin and trypsin did not 
contain plasminogen. Prior to lysis, some clots were overlaid with 5 µM Aβ42 for 1 hr, the 
overlays removed, and the clot surface washed three times with HEPES buffer.  
2.12. Enzyme activity 
Assays were performed at RT in Fisherbrand 96-well plates with a reaction volume of 
150 µl. For plasmin activity, chromogenic substrate Pefa-5329 (Centerchem; 530 µM) was 
added to plasmin (440 nM) with various amounts of Aβ42. For tPA activity, chromogenic 
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substrate S-2288 (Diapharma; 530 µM) was added to tPA (100 nM) with various amounts of 
Aβ42. For tPA-mediated plasminogen activation, plasminogen (440 nM) and tPA (100 nM) 
were mixed with various amounts of Aβ42, and Pefa-5329 was added to monitor plasmin 
generation.  
To monitor plasmin activity and clot turbidity simultaneously and under the same 
reaction conditions, parallel clots were prepared containing fibrinogen (1.5 µM), 
plasminogen (300 nM), tPA (0.15 nM) or streptokinase (Sigma; 0.75 nM), thrombin (0.5 
U/ml), CaCl2 (5 mM) and either Pefa-5329 (400 µM) or buffer only (modified from 137,138). 
Readings were taken at dual wavelengths of 405 nm (A405) and 350 nm (A350). Plasmin 
activity was detected in the samples containing Pefa-5329 at A405, from which the signal 
arising from the changing turbidity (A405) of the forming and lysing clot without Pefa-5329 
was subtracted. Clot turbidity and plasmin activity were plotted together to best visualize the 
temporal relationship of the two processes.  
Fibrin monolayers were overlaid with 60 µl of Aβ42 (2 µM) or vehicle in PBS and 
incubated for 18 hrs at 4°C. The Aβ was removed, and the well surface washed three times 
with PBS containing 0.05% Tween-20. Fibrin monolayers or control wells were then overlaid 
with 150 µM of plaminogen (300 nM) and tPA (1.5 nM), and plasmin activity measured with 
530 µM of the chromogenic substrate Pefa-5329.  
2.13. Clot structure and binding studies: Laser scanning confocal microscopy  
Samples were visualized at RT using a Zeiss LSM 510 confocal laser scanning system 
and a Zeiss Axiovert 200 microscope with a 40x-Axiovert 1.2/water objective (3x optical 
zoom) at the Rockefeller University Bio-Imaging Resource Center. Laser scanning was done 
in multi-track scanning mode with excitation at 488 nm and emission at 500-530 nm (for 
Alexa Fluor 488 fibrinogen) and excitation at 543 nm and emission at 565-615 nm (for 555 
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HiLyte Fluor Aβ). All images were acquired using LSM 510 version 3.2 software (Zeiss) 50 
µm above the glass surface. Five µm z-stacks taken every 0.5 µm (11 slices per image) 
were projected two dimensionally to produce the final image.  
Aβ binding to fibrin(ogen): Clots (30 µM final volume) were formed in 1.5 mm glass-
bottom dishes (Mattek). Fibrinogen (2.7 µM) and Alexa-Fluor 488 fibrinogen (Invitrogen; 0.3 
µM) were mixed with thrombin (0.5 U/ml) and CaCl2 (5 mM) in 20 mM HEPES (pH 7.4) with 
140 mM NaCl with or without Aβ. For clots with Aβ, non-labeled Aβ42 (1.5 µM) was mixed 
with HiLyte Fluor 555 Aβ42 (1.5 µM) or HiLyte Fluor 555 Aβ(1-9) (1.5 µM). Clots were 
incubated in the dark at 37°C for 1 hr prior to imaging. For overlay experiments, clots formed 
as described were overlaid with HiLyte Fluor 555 Aβ42 (3 µM), HiLyte Fluor 555 Aβ(1-9) (3 
µM) or vehicle for 1 hr, the overlays removed, and the clot surfaces washed with HEPES 
buffer. The fluorescent label does not alter Aβ’s ability to delay clot lysis (not shown). For 
some experiments, clots were visualized in the absence of fluorescently labeled Aβ but with 
Aβ42 or Aβ42 I31P (1.5 µM).  
Plasminogen binding to fibrin: Clots (30 µM final volume) were formed in 1.5 mm glass-
bottom dishes with fibrinogen (3 µM), fluorescein isothiocyanate (FITC) labeled Glu-
plasminogen (Oxford Biomedical; 125 nM), thrombin (0.5 U/ml), CaCl2 (5 mM), with or 
without Aβ42 (5 µM) in 20 mM HEPES (pH 7.4) buffer with 140 mM NaCl. Samples were 
visualized as above, but using single track mode with excitation at 488 nm and emission at 
500-530 nm. Five sections were captured from random locations in three separate control 
and Aβ-influenced clots. Representative 5 µM z-stacks composed of 11 slices and projected 
two dimensionally were also acquired for each control and Aβ-containing clot. FITC-
plasminogen binding to fibrin was analyzed using ImageJ130, with total fluorescence in each 
section used as a measure of plasminogen binding.  
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2.14. Plasminogen binding to fibrin monolayer: ELISA 
Fibrin monolayers were incubated with Aβ42 (2 µM) or vehicle for 18 hrs at 4°C. Non-
bound Aβ was removed and the monolayers washed with PBS with 0.05% Tween-20 three 
times. Plasminogen (500 nM) was then applied to the monolayers in PBS with 4% milk and 
0.01% Tween-20 for 2 hrs at 37°C. Plasminogen was removed, and monolayers washed 
with PBS with 0.05% Tween-20 three times. Monoclonal plasminogen antibody 10A1 (Santa 
Cruz; 1:2000) in PBS with 4% milk and 0.01% Tween-20 was applied to the monolayer for 1 
hr at RT. After washing, HRP-conjugated anti-mouse antibody (GE Healthcare; 1:5000) in 
the same buffer was applied for 1 hr at RT. After washing, the ELISA was developed using a 
tetramethylbenzidine (TMB) peroxidase substrate (Vector Labs) and reactions stopped 
using 1N H2SO4. Absorbance was measured at 450 nm. All conditions were tested in 
triplicate.  
2.15. Preparation of Aβ for FXII activation studies 
Aβ42, Aβ40, and Aβ42 E22Q Dutch (Anaspec) monomers and oligomers were prepared 
as in 139 with some modifications. Aβ peptides were monomerized by treatment with 
hexafluoroisopropanol (Sigma-Aldrich). Monomerized Aβ was dissolved to 5 mM with 
dimethyl sulfoxide (Sigma-Aldrich). For monomer (fresh) preparations, Aβ was dissolved to 
100 µM in ultrapure ice-cold water and used immediately. For oligomers, Aβ in DMSO was 
dissolved to 100 µM in Ham’s F12 medium (Caisson Labs) and incubated at 4°C for 16 hrs 
with rotation. For fibrils, non-monomerized Aβ42 was dissolved into a minimum volume of 
1% NH4OH, then adjusted to 200 µM with tris buffered saline (TBS) and incubated at 37°C 
with shaking for 7 days. All Aβ preparations were confirmed by TEM.  
2.16. Human blood collection and plasma preparation 
Studies with human volunteers were approved by the Rockefeller University Institutional 
Review Board or by the Karolinska Institute. Blood was drawn from 10 healthy volunteers 
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giving informed, written consent using 21 gauge 0.75 inch butterfly needles (BD) with a 
multi-adapter for S-Monovette (Sarstedt) into S-Monovette 5 ml tubes containing 1/10 
volume 0.106 mM trisodium citrate solution at the Rockefeller University Hospital and 
Karolinska Institute Hospital. To obtain platelet rich plasma (PRP), blood was centrifuged at 
130 x g for 10 min at RT, and the top 1/2 of the PRP removed. To obtain platelet poor 
plasma (PPP), blood was centrifuged twice at 2000 x g for 10 min at RT. PPP was frozen 
immediately at -80°C. All experiments with PRP and PPP were repeated using plasma from 
at least 3 volunteers. 
2.17. Mouse lines  
For thrombin generation experiments, FXII-/- and FXI-/- mice backcrossed for >10 
generations140,141 and age-matched C57Bl/6 control mice (Charles River) were used.  
For brain immunofluorescence and Western blot experiments, transgenic Tg6799 
(Jackson Laboratory) and TgCRND8 (kindly provided by A. Chishti and D. Westaway, 
University of Toronto, Canada) mouse models of AD were used. Tg6799 mice are double 
transgenic for APP/Presenilin 1 and express five familial AD mutations: three in APP 
(K670N/M671L, Swedish; I716V, Florida; V717I, London), and two in Presenilin1 (M146L, 
L286V) under the mouse thy1 promoter. Tg6799 mice develop amyloid plaques at 2 months 
of age and cognitive impairment by 4-5 months of age142. TgCRND8 mice express a double 
mutant form of APP695 (K670N/M671L, Swedish; V717F, Indiana) under the human prion 
protein promoter. TgCRND8 mice develop Aβ pathology and cognitive deficits as early as 3 
months of age143. Non-transgenic littermates were used as controls. For analysis of plasma 
contact system activation, Tg6799 mice and littermate controls were used. For Aβ42 
injection experiments, 2 month old C57BL/6 mice (Jackson Laboratory) were used. 
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2.18. Analysis of thrombin generation in human and mouse plasma 
Real time thrombin generation in normal human plasma or FXII-deficient plasma (from 
individuals genetically deficient in FXII; George King Biomedical) was measured by CAT as 
described in 144. In some cases, plasma was pre-incubated for 30 min with an antibody 
against FXIIa145 or active-site inhibited factor VII (ASIS; Novo Nordisk). Some reactions also 
contained FXIa (3 pM). All samples were run in duplicate, and curves are representative of 
at least 3 separate experiments run with plasma from different donors (for normal plasma). 
Real time thrombin generation in FXII-/-, FXI-/-, and C57Bl/6 mouse plasma was measured 
as described above, except a smaller amount of mouse PPP (40 µl) was used to obtain 
stronger signal (as in 146). 
2.19. Analysis of FXII, FXI, and prekallikrein activation in vitro  
Chromogenic substrate assay: Assays were performed at 37°C in flat-bottom 96-well 
polystyrene plates (Fisher Scientific) coated with 1% Polyethylene glycol 20,000 in HEPES-
buffered saline (HBS) for 2 hrs. To measure FXII activation, Pefachrome FXIIa (H-D-CHA-
Gly-Arg-pNA-2AcOH; Centerchem), final concentration 0.8 mM, was added to a mixture 
containing 100 nM FXII (Haematologic Technologies) and 3 µM Aβ or vehicle. To measure 
FXII-dependent prekallikrein activation, Pefachrome PK (H-D-But-CHA-Arg-pNA-2AcOH; 
Centerchem), final concentration 0.8 mM, was added to a mixture containing 10 nM FXII, 10 
nM plasma prekallikrein (Enzyme Research Laboratories) and 3 µM Aβ or vehicle. To 
measure FXII-dependent FXI activation, Pefachrome FXIa (Z-Aad-Pro-Arg-pNA-AcOH; 
Centerchem), final concentration 0.8 mM, was added to a mixture containing 5 nM FXII, 15 
nM FXI (Haematologic Technologies), and 3 µM Aβ or vehicle. Enzyme activity was 
detected as change in absorbance at 405 nm every 45 s using a Molecular Devices 
Spectramax Plus 384 microplate reader. 
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Western blot: Coagulation factor activation was analyzed in a purified protein system 
and in human plasma. For FXII activation, FXII (200 nM) was incubated with Aβ42 (3 µM), 
dextran sulfate 500 kDa (DS500; Sigma; 10 µg/ml), or vehicle for 30 min at 37°C. In some 
experiments, prekallikrein (150 or 300 nM) and high molecular weight kininogen (HK; 300 
nM) were added to the reaction. Reactions were stopped by adding reducing sample buffer 
and heating for 5 min at 85°C. Immunoblots were probed with an antibody against FXII 
(Hematologic Technologies). For FXI activation, FXII (200 nM), prekallikrein (150 nM), HK 
(Molecular Innovations; 300 nM), and FXI (150 nM) were incubated with Aβ (3 µM), kaolin 
(Fisher; 100 µg/ml), DS500 (10 µg/ml), or vehicle for 30 min at 37°C. Immunoblots were 
probed with a monoclonal antibody against FXI (Haematologic Technologies). For 
prekallikrein activation and HK cleavage, FXII (40 nM), prekallikrein (60 nM), and HK (60 
nM) were incubated for 5 min at 37°C, and immunoblots were analyzed using a polyclonal 
antibody against plasma prekallikrein (Affinity Biologicals) or a monoclonal antibody against 
the light chain of HK (Abcam). For experiments in human plasma, plasma from healthy 
volunteers or FXII-deficient plasma was diluted 1:10 in HBS and incubated with activators 
for 1 hr at 37°C followed by Western blot analysis using the antibodies described above. For 
FXII activation, plasma was incubated with Aβ42 (20 µM). For prekallikrein activation, 
plasma was incubated with Aβ42 (20 µM) or kaolin (100 µg/ml). For HK cleavage, plasma 
was incubated with various concentrations of Aβ and kaolin. 
ELISA: Normal human plasma or FXII-deficient plasma were diluted 1:10 in HBS buffer 
and incubated with Aβ42, Aβ42 Dutch (20 µM), kaolin (10 µg/ml), or vehicle at 37°C for 1 hr. 
Reactions were transferred to a 96-well plate pre-coated with a monoclonal antibody against 
FXI (3 µg/ml) overnight at 4°C, washed with PBS containing 0.05% Tween-20 (PBS-T), and 
blocked with PBS containing 2% milk (blocking buffer) for 1 hr at RT. Reactions were 
incubated in wells for 1 hr at RT, removed, and wells washed 3 x 5 min with PBS-T. A 
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polyclonal antibody against C1 inhibitor (Cedarlane) or alpha-1-antitrypsin (3 µg/ml; Thermo 
Scientific) in blocking buffer was applied to the wells for 1 hr at RT. After washing, an HRP-
conjugated anti-goat antibody (Jackson; 1:2000) in blocking buffer was applied for 1 hr at 
RT. The ELISA was developed with TMB peroxidase substrate (Thermo Scientific). 
Absorbance was measured at 450 nm. All conditions were tested in triplicate. 
2.20. Binding between Aβ and FXII, FXI 
N-terminally biotinylated Aβ42 (200 nM) was incubated with FXII (200 nM) or FXI (100 
nM) in PBS containing 0.01% NP-40 and protease inhibitor cocktail for 2 hrs at RT. 
Pulldown assays were performed as described above and analyzed by Western blot using 
monoclonal antibodies against FXII and FXI (Haematologic Technologies). For pulldown 
assays in normal human plasma, plasma was diluted 1:5 in PBS containing 0.01% NP-40 
and protease inhibitor cocktail and incubated with biotinylated Aβ42 (500 nM) or N-terminally 
biotinylated amylin (500 nM; Anaspec) for 2 hrs at RT.  
2.21. AD patient and control plasma samples  
Experiments with human plasma were approved by the Rockefeller University 
Institutional Review Board. Plasma from AD patients and ND controls was obtained from the 
University of Kentucky Sanders-Brown Center on Aging (Group 1) and Washington 
University Knight Alzheimer’s Disease Research Center (Group 2). For Group 1, blood from 
18 AD and 11 ND individuals giving written, informed consent was drawn into heparinized 
Vacutainer tubes with a 23 or 21 gauge needle. AD cases were defined by a clinical 
diagnosis of AD as well as a postmortem Consortium to Establish A Registry for Alzheimer’s 
Disease (CERAD) neuritic plaque score147 of B or C, corresponding to probable or definite 
AD, respectively. ND cases had CERAD scores of 0 and no clinical diagnosis of AD. AD and 
ND cases were gender and age-matched (Table 1). For Group 2, blood from 10 AD and 10 
ND individuals was drawn using EDTA-coated syringes into polypropylene tubes containing 
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a final concentration of 5 mM EDTA. Plasma was prepared by centrifuging blood at 2000 x g 
for 15 min, and flash frozen on dry ice prior to storage at -80°C. AD cases were defined by a 
Clinical Dementia Rating (CDR) score14 of ≥0.5 and CSF Aβ42 levels <500 pg/ml, and ND 
cases were defined by a CDR score of 0 and CSF Aβ42 levels >500 pg/ml (Table 2). CSF 
Aβ42 cut-off values for AD vs. ND were based on correlations between CSF Aβ42 levels 
and cortical amyloid load as assessed by positron emission tomography with Pittsburgh 
Compound B148.  
2.22. Analysis of contact system activation in AD patient plasma by Western blot 
Plasma protein concentration was measured by BCA, and equal amounts of total protein 
(20 µg) from each sample were analyzed by non-reducing or reducing Western blot with 
monoclonal antibodies against FXII heavy chain (Haemotologic Technologies), HK light 
chain (Abcam), FXI (Haematologic Technologies), C1 esterase inhibitor (Proteintech), and 
transferrin (Abcam). Purified FXI, FXII, HK, C1 inhibitor (Athens Research and Technology), 
and FXII-deficient plasma were loaded as positive controls for some experiments. 
2.23. Measurement of kallikrein-like activity in human and mouse plasma 
Plasma kallikrein-like activity was measured using the chromogenic substrate S-2302 
(Chromogenix) based on the method described in 149 with some modifications. Plasma 
(diluted 1:30) in 20 mM HEPES with 140 mM NaCl was mixed with S-2302 (0.67 mM final 
concentration) in duplicate, and absorbance at 405 nm was read for 30 min at RT in a 
Molecular Devices Spectramax 384 Plus spectrophotometer. The rate of substrate 
conversion over time was calculated for each plasma sample by the data acquisition 
software (Softmax 6.1; Molecular Devices), and expressed as a percentage of the rate 
found for normal human or wild type mouse plasma fully activated with dextran sulfate 500 
kDa. S-2302 can also be cleaved by FXIIa, FXIa, and plasmin. To determine whether S-
2302 cleavage was mediated by members of the contact activation pathway (kallikrein, 
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FXIIa, or FXIa) or plasmin, plasmin activity in all samples was determined using a different 
substrate (Pefachrome-5329, Pentapharm) and found not to differ between AD and ND 
plasma (not shown). 
2.24. Analysis of contact system activation in AD mouse plasma 
All animal experiments were conducted in accordance with the guidelines of the US 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and with 
approval from the Animal Care and Use Committee of The Rockefeller University. Tg6799 
mice (n=7) or littermate control mice (WT; n=7) at 6 months of age were anesthetized with 
atropine (500 mg/kg body weight) and avertin (0.04 mg/kg body weight) intraperitoneally. 
Blood (100 µl) was collected via retro-orbital bleeding through gel-repel (Sigma) and 
polybrene (Santa Cruz) coated capillaries into EDTA-coated tubes (BD) containing 5 mM 
EDTA. Plasma was prepared by centrifugation (1500 x g for 15 min, twice), and stored in 
polypropylene tubes containing 5 mM EDTA. Total protein concentration was determined by 
BCA, and plasma from each mouse containing 20 µg total protein was analyzed by Western 
blot using monoclonal antibodies against HK light chain (R&D) and transferrin (Abcam) in 
that order. Blots were stripped between antibody incubations. Protein levels were quantified 
by densitometric analysis.  
2.25. Analysis of contact system activation in C57Bl/6 mice injected with Aβ  
Aβ42, scrambled Aβ42, and amylin (Anaspec) were prepared as follows: peptides were 
resuspended in a minimum amount of 1% NH4OH, then diluted to 1 mg/ml with PBS. 
Peptide concentration was determined by BCA, and the state of aggregation was 
determined by TEM. Aβ42, scrambled Aβ42, amylin, or vehicle (6 mg/kg body weight) were 
administered via retro-orbital injection into 2 month-old C57BL/6 mice under anesthesia 
using avertin and atropine as described above. After 6 hrs, blood was collected and 
processed as described above. Western blot analysis was performed as described above. 
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Levels of plasma Aβ42 were determined at 6 hrs post injection using an Aβ42-specific 
ELISA kit (Life Technologies) according to the manufacturer’s instructions.  
For analysis of the effect of different anticoagulants on ex-vivo contact activation, plasma 
from non-injected WT mice was collected into EDTA or heparin tubes. Plasma was then 
incubated with 20 µM Aβ42, scrambled Aβ42, amylin, or vehicle for 1 hr at 37°C, then 
analyzed by Western blot as described above. 
2.26. Analysis of brain tissue in AD patients and mouse models 
Immunofluorescence: Mice were saline/heparin-perfused and brains were fixed in 4% 
paraformaldehyde, cryoprotected in 30% sucrose, and frozen. Coronal sections (20 µm) 
were blocked for 1 hr in PBS containing 0.25% Triton X-100 and 3% donkey serum 
(Jackson Laboratory), incubated overnight at 4°C with anti-Aβ monoclonal antibody 6E10 
(Covance) and FXII antibodies (Novus, HTI), followed by 1 hr incubation with Alexa-Fluor 
secondary antibodies. Controls for secondary antibody non-specific binding were performed 
by omitting primary antibodies. Sections were dehydrated and cover slips were applied with 
Vectashield (Vector labs). Images were acquired using an inverted TCS SP8 laser scanning 
confocal microscope (Leica DMI 6000) at the Rockefeller University’s Bio-Imaging Resource 
Center and analyzed by ImageJ. 
Western blot: Mouse (whole brain) and human (temporal pole) frozen tissue was 
homogenized in 5 volumes (g/ml) of PBS containing 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS, and protease inhibitor cocktail (Roche). The homogenates were centrifuged at 
10,000 x g for 10 min at 4°C to yield a supernatant containing the soluble protein fraction. 
Protein concentration was determined by BCA, and equal amounts were run on a 10% 
polyacrylamide Criterion gel (Bio-Rad) followed by Western blot analysis with the following 
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antibodies: murine HK (R&D Systems), tubulin (Abcam), human HK light chain (Abcam), 
actin (Abcam), albumin (Thermo Scientific), hemoglobin (Abcam), and fibrinogen (Dako).  
2.27. Antibodies  
 
Table 2.1. List of antibodies used 
Antigen Details Source Applications 
Aβ Mouse monoclonal 6E10 Covance immunofluorescence 
Aβ Mouse monoclonal 3D6 Elan Western blot 
Actin Chicken polyclonal Abcam Western blot 
Albumin Goat polyclonal Thermo Scientific Western blot 
Alpha-1-antitrypsin Goat polyclonal MyBioSource ELISA 
C1 esterase inhibitor Goat polyclonal Cedarlane ELISA 
C1 esterase inhibitor Rabbit polyclonal Proteintech Western blot 
Fibrinogen Rabbit polyclonal Dako Western blot 
FXI Mouse monoclonal Hameatologic Technologies ELISA, Western blot 
FXII Mouse monoclonal Haematologic Technologies Western blot 
FXII Rabbit polyclonal Novus Immunofluorescence 
FXII Sheep polyclonal Haematologic Technologies Immunofluorescence 
FXIIa Fully human monoclonal 3F7 Larsson et al. 
145 Inhibition studies 
Hemoglobin Rabbit monoclonal Abcam Western blot 
HK (human) Rabbit monoclonal to light chain Abcam Western blot 
HK (mouse) Rat monoclonal to light chain R&D Western blot 
Plasminogen Mouse monoclonal 10A1 Santa Cruz ELISA 
Prekallikrein Sheep polyclonal Affinity Biologicals Western blot 
Transferrin (human) Rabbit polyclonal Abcam ab88165 Western blot 
Transferrin (mouse) Rabbit polyclonal Abcam ab82411 Western blot 





2.28. Statistical analysis 
Data are presented as column graphs with mean ± standard deviation (SD) or as vertical 
scatter plots with medians and reported as means ± SD or medians in the text. Unless 
otherwise indicated, comparisons between two groups were performed using the unpaired, 
two-tailed t-test for parametric data or using the two-tailed Mann-Whitney test for non-
parametric data. Comparisons between multiple groups were performed using Kruskal-
Wallis test followed by Dunn’s Multiple Comparison Test. For some experiments, 
comparisons between groups were performed using 1 way ANOVA followed by Dunnett’s 
Multiple Comparison Test for multiple groups with a single control. Two-way ANOVA with 
Bonferroni post-test was used for comparisons between groups affected by two factors. 
Correlation analysis was performed using Pearson’s correlation coefficient (r). P values 
≤0.05 were considered significant (*), with values ≤0.01 designated (**), values ≤0.001 
designated (***), and values ≤0.0001 designated (****) in figures. Statistical analyses were 




CHAPTER 3. Mechanisms through which binding between Aβ42 and fibrinogen lead 
to delayed fibrinolysis  
3.1. Background 
If the prothrombotic state observed in AD patients and mouse models contributes to AD 
etiology, a better understanding of the mechanisms responsible for eliciting such a state is 
crucial. One way to achieve a prothrombotic state is through impaired fibrin degradation 
(fibrinolysis), which could prevent timely clearance of clots as well as increase the likelihood 
that clots will form, since the thrombotic-fibrinolytic equilibrium during clot formation would 
be disturbed. In this regard, the Strickland laboratory has shown that clots formed in the 
presence of Aβ42 are structurally altered and more resistant to fibrinolysis than normal 
clots59, and that fibrinogen, the main protein component of clots, can bind Aβ42 specifically 
with a Kd of 26.3 ± 6.7 nM125. However, the mechanisms by which Aβ42-fibrin(ogen) binding 
delays fibrin clot lysis have not been defined. To better understand how Aβ42 binding to 
fibrin(ogen) can result in abnormal clot structure and to the decreased susceptibility of the 
fibrin clot to fibrinolysis, I investigated the biochemical and structural details of the Aβ42-
fibrinogen interaction.  
3.2. Biochemical details of the Aβ–fibrinogen interaction 
Binding region for Aβ on fibrinogen. Fibrinogen is a 340 kDa glycoprotein composed of three 
pairs of chains (α, β, and γ) organized into three structural regions, where two identical D 
domains (fragment D) are joined by a central E domain (fragment E; Figure 3.1A). The 
Strickland laboratory has previously shown that Aβ binds to fragment D of fibrinogen125. To 
determine where within fragment D Aβ42 binds, I partially digested fibrinogen, generating 
fibrinogen degradation products (FDPs). FDPs were pulled down using biotinylated Aβ42 
and streptavidin, and the Aβ42-interacting peptides visualized using SDS-PAGE. The ~7 
kDa Aβ-binding fragment (Figure 3.1B; Fragment 1) was analyzed by liquid 
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chromatography-tandem mass spectrometry (LC-MS/MS) at the Rockefeller University’s 
Proteomics Center, which mapped a portion of the ~7 kDa fragment to the C-terminal region 
of the fibrinogen β-chain (β396-407). Consistent with this result, N-terminal sequencing of 
the ~7 kDa fragment placed it within the C-terminal region of the β-chain (β366-370) (Figure 
3.1C). The exact size of the fragment was determined using matrix-assisted laser desorption 
ionization-time of flight (MALDI-TOF) analysis, resulting in a mass corresponding to 49 
amino acids, placing it between β366 and β414 (Figure 3.1C). These results indicate that 
Aβ42 interacts with fibrinogen near the C-terminus of the fibrinogen β-chain, a region that 
encompasses the functional domain called the b-hole (within the globular β-chain domain; 
green in Figure 3.1A). The 49 amino acid peptide (β366-414) corresponding to the identified 
fragment was synthesized at Rockefeller University’s Proteomics Resource Center, and its 
ability to bind Aβ42 was confirmed by pulldown assay (Figure 3.1D) and by AlphaLISA 
assay by Hyung Jin Ahn125, which demonstrated the ability of the 49-mer to inhibit Aβ-









Figure 3.1. Localization of the Aβ42 binding site within fibrinogen fragment D. (A) 
Fibrinogen is composed of two sets of α, β, and γ chains and organized into an E domain 
flanked by two D domains (adapted from 150). (B) Biotinylated Aβ42 pulled down two 
plasmin-generated fibrinogen degradation products (FDPs). Only the ~7 kDa fragment was 
analyzed successfully. (C) The ~7 kDa fragment mapped to the C-terminus of the fibrinogen 
beta chain by N-terminal sequencing and LC-MS/MS. MALDI-TOF identified 49 amino acids 
in the fragment. (D) Silver-stained SDS-PAGE showing that biotinylated Aβ42 pulls down 




Binding region for fibrinogen on Aβ. To determine which region of Aβ42 is responsible 
for fibrinogen binding, fibrinogen and fragment D were pulled-down with biotinylated sub-
regions of Aβ42. Fragments Aβ17-40 and Aβ22-41 had the strongest affinity for fragment D, 
while Aβ1-16 had the least (Figure 3.2A, top), indicating that the C-terminal two thirds of the 
molecule are involved in binding fragment D. Pulldown of fibrinogen with the same Aβ sub-
regions yielded similar results, although more binding was detected to N-terminal Aβ 
peptides (Figure 3.2A, bottom), suggesting that fibrinogen may have additional Aβ binding 
sites outside of fragment D which may be mediated by N-terminal Aβ residues. This 
interpretation is supported by data demonstrating an additional binding site for Aβ42 on the 
fibrinogen α chain outside of fragment D (not shown, in collaboration with Hyung Jin Ahn). 
Consistent with the binding site for fragment D on Aβ being located closer to its C-terminus, 
incubation of biotinylated Aβ42 with fragment D in the presence of increasing concentrations 










Figure 3.2. Localization of the fibrinogen binding site on Aβ42. Western blots showing 
streptavidin pulldown assays probed with a polyclonal anti-fibrinogen antibody (Dako). (A) 
Biotinylated Aβ fragments were used to pull down fibrinogen fragment D or fibrinogen. (B) 




3.3. Structural details of the Aβ–fibrinogen interaction 
Structural details of the Aβ42-fibrinogen interaction were investigated via X-ray 
crystallography in collaboration with Hyung Jin Ahn and under the guidance of Deena Oren 
of The Rockefeller University’s Structural Biology Resource Center. We sought to obtain a 
crystal structure of the complex between Aβ42 and fragment D, due to results indicating that 
fragment D is the major binding region for Aβ on fibrinogen and to the smaller size and ease 
of manipulation of fragment D.  
Our strategy was to soak Aβ42 into pre-formed fragment D crystals due to the large 
solvent channels present in the fragment D structure. Fragment D crystals were obtained 
using the method of 129 as detailed in Methods 2.7 (Figure 3.3A), and the ability of Aβ42 to 
penetrate into the crystal lattice was tested by soaking fragment D crystals with fluorescently 
labeled TAMRA (5-Carboxy-tetramethylrhodamine)-Aβ42. Non-specifically bound TAMRA-
Aβ42 was removed by repeatedly washing the crystal until no decrease in fluorescence was 
observed. Persistent fluorescence confirmed binding of Aβ42 within the crystals (Figure 
3.3B). One challenge presented by soaking Aβ42 into fragment D crystals is the rapid 
oligomerization of Aβ42, resulting in a wide range of species. To circumvent this problem, 
we soaked crystals with the synthetic Aβ42 mutants I31P and G37D, which are less prone to 
aggregation151,152, but can still bind fragment D (Figure 3.3C). Crystals were also soaked in 
Aβ42, Hylite fluor 555-labeled Aβ42, or not soaked at all, and data sets were collected at the 
National Synchrotron Light Source. The structure was solved by molecular replacement as 
described in Methods 2.7. Soaking of Aβ42 did not damage fragment D crystals, since in 
most cases the space groups and unit cell dimensions obtained were isomorphous with 
dimensions found in unsoaked (native) crystals, and relatively well with published 
dimensions for fragment D129 (Figure 3.3D). Analysis of electron density showed subtle 
changes to the structure of fragment D soaked with all Aβ42 preparations compared to data 
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obtained for a native (unsoaked) crystal, suggesting interaction between fragment D and 
Aβ42. Specifically, a loop in the fragment D β-chain (β384-393), which forms part of the 49 
amino acid Aβ42 binding region identified in Figure 3.1, was shifted away from the coiled 
coil region in multiple crystals soaked with Aβ42 and 555-Aβ42 (Figure 3.3E; data shown 
only for Aβ42-soaked crystal). This loop is shifted in a similar but not as dramatic a manner 
in fragment D structures crystallized in the presence of b-hole binding peptides (as in PDB 
1FZG153, among others; Figure 3.5F), suggesting that Aβ interacts with residues near the b-
hole. Peptides binding the b-hole also induced a flip in a nearby loop (β395-400), which was 
not observed in our structure, suggesting that Aβ may not fit all the way in the b-hole as the 
peptides do. We also observed patches of density unaccounted for by the fragment D 
coordinates possibly corresponding to Aβ42. These patches of density were found in the 
region of fragment D in special proximity to the 49 amino acid binding site on the β-chain the 






Figure 3.3. Altered fragment D structure in the presence of Aβ42. (A) Bright field (left) 
and UV fluorescence (right) images of fragment D crystals, indicating crystals are 
proteinacious. (B) Left: Bright field image of a fragment D crystal that had been subjected to 
soaking in TAMRA-Aβ42 followed by extensive washing. Right: Persistent red fluorescence 
after washing indicated that TAMRA-Aβ42 was binding within the crystal. (C) Western blot 
analysis of a pulldown assay demonstrating that Aβ42 I31P and Aβ42 G37D bind to 
fragment D. The blot was probed with antibodies against fibrinogen (top) and Aβ (bottom) to 
demonstrate Aβ pulldown by biotinylated fragment D. (D) Unit cell dimensions of published, 
non-soaked, and Aβ42-soaked fragment D crystals. Only Aβ42-soaked crystal unit cell 
dimensions are shown, since data from other Aβ peptide soaks were similar. (E) Diagram of 
fibrinogen indicating fragment D (FD; dashed line box) and where differences between non-
soaked and Aβ42-soaked fragment D crystals were found (solid line box). Superimposed 
2Fo-Fc maps from non-soaked (pink; Rwork/Rfree = 0.24/0.33) and Aβ42-soaked (blue; 
Rwork/Rfree = 0.28/0.39) fragment D crystals with coordinates of non-soaked crystals. (G) 
Protein backbone diagram showing the shift of the β384-393 loop from native (1FZA) to b-
hole-peptide bound (1FZG) fragment D.   
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3.4. Mechanism of fibrin formation and fibrinolysis 
Upon exposure to thrombin, fibrinogen undergoes cleavage at the N-termini of its α and 
β chains within the central E domain to reveal A- and B-knobs, respectively, yielding a fibrin 
monomer. These knobs can interact with corresponding a- and b-holes in the D domains of 
an adjacent fibrin(ogen) molecule to begin the process of fibrin polymerization (Figure 3.4, 
blue panel). Fibrin monomers polymerize end-to-end into two-stranded protofibrils, which 
then aggregate laterally into fibrils, which branch to form a gelationous fibrin network (Figure 
3.4, green panel).  
Fibrin clot degradation (fibrinolysis) is mediated by plasmin, a serine protease that 
cleaves the fibrin network at specific sites, generating fibrin degradation products (Figure 3.4, 
yellow panel). Plasmin is derived from the zymogen plasminogen by tissue plasminogen 
activator (tPA) in the presence of fibrin, which itself enhances the rate of the reaction. One 
fibrin site initially involved in plasminogen activation by tPA includes residues 148-160 on 
the α-chain (Figure 3.4, pink panel; reviewed in 154). This site becomes exposed and 
available for plasminogen binding after the conversion of fibrinogen to fibrin155, but could 
remain hidden if clots are formed in the presence of Aβ, leading to delayed clot lysis. This 
hypothesis is derived from our data indicating that Aβ binds the fibrinogen β-chain near the 
b-hole (Figure 3.1 and 125), which is in close spatial proximity to residues 148-160 of the α-
chain (Figure 3.4, pink panel and 132). Another potential explanation for delayed clot lysis is 
based on the relationship between fibrin structure and its susceptibility to fibrinolysis. Tighter 
fibrin networks composed of thin fibers are degraded less efficiently by plasmin than those 
composed of thick fibers138,156-158 because 1) there are more fibers to be cleaved157,159, 
requiring plasmin to detach from and move between fibers more frequently160; and 2) 
decreased network porosity of tighter fibrin networks results in impeded diffusion of 
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fibrinolytic enzymes throughout the clot (reviewed in161). Potential effects of Aβ on fibrin fiber 
thickness could thus be another mechanism of Aβ-mediated impaired fibrinolysis.  
To determine the mechanism of Aβ42-mediated delay of fibrinolysis, I investigated the 
effects of Aβ42 itself and of the Aβ2-influenced fibrin network on the activity and function of 







Figure 3.4. Fibrin formation and fibrinolysis. Cleavage of fibrinopeptides A and B within 
fibrinogen fragment E results in the formation of a fibrin monomer with exposed A- and B-
knobs. These knobs interact with the a- and b-holes of fragment D domains on nearby fibrin 
monomers to begin the process of fibrin polymerization (blue panel). Fibrin monomers 
polymerize end-to-end into two-stranded protofibrils, which aggregate laterally into fibrils 
(green panel). Fibrinolysis is initiated by binding of plasminogen and tPA to the forming fibrin.  
The binding site for plasminogen on residues 148-160 of the α-chain is cryptic in fibrinogen 
(blue panel) but becomes exposed in polymerizing fibrin (pink panel). Activation of bound 
plasminogen to plasmin by tPA results in plasmin-mediated cleavage of the fibrin network 





3.5. Aβ42 present during or after clot formation results in delayed fibrinolysis  
The effect on clot lysis of an Aβ42 preparation containing a mixture of monomeric, 
oligomeric, and fibrillar species (Figure 3.5A, inset) was evaluated using two methods. In 
one method, tPA was added to the clotting mixture at the start of clot formation to simulate 
internal fibrinolysis, which is thought to approximate physiological conditions163. Lysis rates 
were compared using half-lysis times, which were calculated as the time from when 
maximum turbidity was achieved to when the clot reached half its maximum turbidity. The 
effect of Aβ42 on clot lysis was tested over a wide range of tPA concentrations (Figure 3.5A; 
only one tPA concentration shown for clarity), since tPA levels can increase dramatically 
from their base levels in response to injury. A significant delay in lysis relative to control was 
observed at all three tPA concentrations tested (Figure 3.5B), suggesting that the effect may 
be relevant in chronic as well as acute injury states. Furthermore, the delay in lysis is Aβ 
concentration-dependent, with concentrations from 500 nM to 3 µM producing significant 
and increasing delays in lysis (Figure 3.5C,D). In a complementary method, pre-formed clots 
made with or without Aβ42 were overlaid with tPA to initiate fibrinolysis, a system that is 
more relevant to the pharmacological treatment of thrombosis163. In this system, half lysis 
time was defined as the time from tPA overlay until the clot reached half its maximum 
turbidity, and was significantly increased for Aβ42-containing clots (Figure 3.5E,F). 
Aβ42 can adopt β-sheet structure, and it is possible that β-sheet structure alone was 
responsible for delayed fibrinolysis. However, clots formed with the amyloid peptide amylin, 
which had been aged and confirmed by TEM to contain fibrils (Figure 3.5G, inset), did not 
exhibit delayed lysis (Figure 3.5G). Furthermore, a truncated Aβ peptide (Aβ1-28) had no 
effect on clot lysis (Figure 3.5H). Thus, β-sheet structure alone is not enough to elicit 







Figure 3.5. Aβ42 delays fibrinolysis in dose-dependent manner. (A) Clot formation and 
lysis were monitored by turbidity assay as described in methods. The presence of 3 µM 
Aβ42 (labeled as Aβ on graphs) in the clotting solution resulted in decreased maximum 
turbidity and delayed fibrinolysis (inset: TEM of Aβ42 used). (B) Time to half-lysis was 
significantly higher for clots formed in the presence of Aβ42 compared to control clots for all 
tPA concentrations tested. (C) Clots were formed with 0.5 µM, 1.5 µM, 3 µM Aβ42, or 
vehicle and 1.5 nM tPA. (D) Time to half-lysis of Aβ42 clots was significantly delayed in a 
dose-dependent manner. (E) Pre-formed clots prepared as described in methods were 
overlaid with 50 nM tPA. (F) Time to half-lysis of Aβ42 clots was significantly higher than 
control clots. (G) Clotting and lysis in the presence of 3 µM amylin confirmed by TEM to be 
fibrillar (inset) did not differ from control. (H) Clotting and lysis in the presence of 3 µM Aβ1-




3.6. Aβ42 does not directly inhibit fibrinolytic enzyme activity 
It is possible that Aβ42 interacts directly with fibrinolytic enzymes in solution and reduces 
their activity. I assessed the effect of a range of Aβ42 concentrations on the activities of tPA 
and plasmin. No effect of Aβ42 on tPA (Figure 3.6A) or plasmin (Figure 3.6B) activity was 
observed. It has been shown that the conversion of plasminogen to plasmin by tPA is 
enhanced in the presence of Aβ42, particularly for aggregated forms of Aβ42164-166. Since 
Aβ42 preparations can vary dramatically, I wanted to exclude the possibility that our 
preparation would decrease the conversion of plasminogen to plasmin. In agreement with 
published results, I found that the generation of plasmin from plasminogen by tPA was 
increased in the presence of Aβ42 in solution (Figure 3.6C). These data indicate that the 
inhibitory effect of Aβ42 on clot lysis exists despite its ability to potentiate the generation of 
plasmin in solution.  
3.7. Aβ42-associated fibrin is a weaker enhancer of plasmin generation and a poorer 
substrate for plasmin cleavage 
Fibrin enhances the activation of plasminogen by tPA, and any changes introduced into 
the fibrin network by Aβ42 could alter the efficiency of tPA/plasminogen interactions with 
fibrin. To evaluate this possibility, I included the plasmin activity-monitoring chromogenic 
substrate Pefa-5329 in clotting reactions, and the rate of plasmin generation was monitored 
during clotting and lysis. Clots formed with Aβ2 showed delayed lysis and had reduced 
plasmin activity compared to control clots (Figure 3.7A,B). Since the reduced activity in 
Figure 3.7A is not due to sequestration of plasminogen by Aβ (not shown) or direct inhibition 
of plasmin activity by Aβ42 (in solution – Figure 3.6B; in clot overlay – not shown) , it implies 
a decrease in the rate of plasmin generation and may reflect Aβ-mediated disruption of the 
interaction between fibrin and tPA/plasminogen. To determine whether the decrease in 
plasmin generation is fibrin-related, I used streptokinase (SK) instead of tPA to activate 
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plasminogen, since the rate of plasminogen activation by SK, unlike tPA, is not enhanced in 
the presence of fibrin. Accordingly, there was no difference in plasmin generation between 
Aβ42 and control when clots were lysed with SK and plasminogen (Figure 3.7C). Despite 
similar rates of plasmin generation, the lysis of Aβ-influenced clots was still delayed with SK-
initiated lysis (Figure 3.7C,D). This result could be due to the reduced capability of SK-
generated plasmin167 to bind or process fibrin fibers in Aβ-influenced clots versus control 
clots. 
To test this possibility, I initiated clot lysis using pre-formed plasmin in order to bypass 
the plasminogen activation step. In agreement with the SK/plasminogen result, we observed 
an increase in half-lysis time of Aβ42-influenced clots compared to control clots (Figure 3.8, 
A and B). Plasmin interacts with fibrin through several binding domains and a catalytic 
domain160. The serine protease trypsin is also able to dissolve fibrin clots160, but in contrast 
to plasmin, it operates entirely through its catalytic domain. When pre-formed clots were 
overlaid with trypsin, no delay of lysis of Aβ42-influenced clots was observed (Figure 3.8, C 
and D), suggesting that Aβ interferes with plasmin’s access to its binding site and not its 











Figure 3.6. Aβ42 does not directly inhibit fibrinolytic enzyme activity. Aβ42 at 1 µM, 5 
µM, and 10 µM or vehicle was combined with (A) tPA and the chromogenic substrate S-
2288 to monitor tPA activity; (B) plasmin and the chromogenic substrate Pefa-5329 to 
monitor plasmin activity; or (C) tPA, plasminogen (plg), and Pefa-5329 to monitor plasmin 







Figure 3.7. Plasmin generation by tPA, but not streptokinase, is decreased in Aβ42-
influenced clots. (A) Fibrinogen, plasminogen, tPA, thrombin, CaCl2, and Pefa-5329 or 
vehicle were mixed with or without 3 µM Aβ42. Absorbance was measured at 350 nm to 
follow clot formation and lysis and at 405 nm to monitor plasmin activity. Curves of A405 
without Pefa-5329 were subtracted from Pefa-5329 A405 curves to control for A405 arising 
from clot turbidity and not plasmin activity. (B) Half-lysis of tPA/plasminogen-lysed clots was 
delayed in the presence of Aβ compared to control (p = 0.011).  (C) Same as (A), except 
streptokinase (SK) was substituted for tPA. (D) Half-lysis of SK/plasminogen-lysed clots was 








Figure 3.8. Aβ42-influenced clots are resistant to lysis by plasmin but not trypsin. (A) 
Pre-formed clots prepared as described in methods with or without 5 µM Aβ42 were overlaid 
with 250 nM plasmin. (B) Half-lysis was significantly slower in clots containing Aβ42 (p = 
0.0001). (C) Pre-formed clots as in (A) were overlaid with 1 µM trypsin. (D) There was no 




3.8. Aβ42 is incorporated into fibrin fibers throughout the clot network 
The Strickland laboratory has previously shown that Aβ42-influenced clots are 
characterized by irregular clusters punctuating the fibrin network, and Congo Red staining 
(which stains amyloid fibrils) suggested that Aβ42 was confined to these clusters59. My 
hypothesis that Aβ42 interferes with plasmin(ogen)’s access to fibrin throughout the fibrin 
network requires its regular distribution along fibrin strands. This prompted me to more 
closely analyze Aβ42 localization within clots. Tracer amounts of Alexa Fluor-488-labeled 
fibrinogen (fibrinogen-488) were used to visualize the fibrin network, and HiLyte Fluor-555-
labeled Aβ42 (Aβ42-555), was used to visualize Aβ42. In agreement with previous results, 
clots formed in the absence of Aβ42 showed a regular fibrin network (Figure 3.9A), while 
clots formed in the presence of Aβ42 contained irregular clusters (Figure 3.9C, E,I). Aβ42-
555 labeling of irregular clusters (Figure 3.9F,H; arrowhead) confirmed our previous 
conclusion that Aβ42 binds to fibrin aggregates. However, the uniform labeling of normal 
fibrin fibrils by Aβ42 (Figure 3.9F,H) showed that it is also distributed throughout the fibrin 
lattice. The striking co-localization between fibrin and Aβ42 is not due to the detection of 
fibrinogen-488 fluorescence in the 555 channel, since clots formed without Aβ42-555 
produced no signal in the 555 channel (Figure 3.9, B and D). Furthermore, omitting labeled 
fibrinogen, but not labeled Aβ42, reproduced the Aβ42-covered fibrin lattice (Figure 3.9, G 
and H). Replacing 555-Aβ42 with 555-Aβ(1-9), which does not cause delayed fibrinolysis 
(not shown), eliminated the co-localization (Figure 3.9, I and J), confirming that the labeling 
reflects specific Aβ-fibrin(ogen) binding and is not a result of nonspecific trapping of the 555-
labeled peptides in the forming fibrin network. Clots made without unlabeled Aβ42 but still 
containing 555-Aβ(1-9) did not have co-localization between fibrin and Aβ(1-9) (not shown), 
precluding the possibility that unlabeled Aβ42 blocks access of 555-Aβ(1-9) to fibrin. The 
specific Aβ42-fibrin co-localization found in these experiments, together with the previously 
described spatial proximity of Aβ42 and plasminogen binding sites on fibrin(ogen)125,132, 
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suggested that Aβ42 could block plasmin(ogen) from accessing its binding sites on fibrin. 
However, another potential mechanism became apparent: Aβ42-influenced fibrin is 
composed of thinner fibers arranged in a tighter network than control fibrin (Figure 3.9, A vs. 







Figure 3.9. Aβ42 binds to fibrin fibrils and alters fibrin structure. Fibrin clots were 
formed with or without Aβ42 as described in methods to determine the location of Aβ42 
binding. (Top row) Fibrin visualized with Alexa-488 labeled fibrinogen (green); (Bottom row) 
Aβ visualized with HiLyte Fluor 555-labeled Aβ42 (red); (A,B) Control clot. (C,D) Clot with 
only unlabeled Aβ42 shows that fibrin fibers and irregular clusters do not produce signal in 
the red channel. (E,F) Clot formed with unlabeled Aβ42 and HiLyte Fluor 555 labeled Aβ42 
shows co-localization between Aβ42 and fibrin fibers as well as Aβ42 and irregular clusters 
(arrowhead). (G,H). Clot formed without Alexa-488 labeled fibrinogen but with both 
unlabeled and labeled Aβ42 shows Aβ42 signal in the fibrin fiber pattern, confirming that 
Aβ42 signal is not Alexa-488 signal detected in the red channel. (I,J) Clot formed with 
unlabeled Aβ42 and HiLyte Fluor 555-labeled Aβ(1-9) does not have Aβ(1-9) signal along 
fibrin fibers or in aggregates, indicating that the Aβ42 signal represents specific Aβ42-





3.9. Binding of plasminogen to fibrin and plasmin generation are decreased in the 
presence of Aβ42  
I next tested if Aβ42 binding to fibrin affected the ability of plasminogen to bind to fibrin 
using two complementary approaches: confocal microscopy of clots formed with FITC 
labeled plasminogen and ELISA with an antibody against plasminogen. Confocal 
microscopy of clots formed with FITC-plasminogen showed plasminogen binding as 
fluorescence in the pattern of the fibrin network to which it was bound (Figure 3.10A). 
Fluorescence was decreased in clots containing Aβ42 (Figure 3.10B), suggesting that less 
plasminogen was bound to the fibrin network (plasminogen does not bind to Aβ; not shown). 
The amount of plasminogen binding was quantified as total fluorescence intensity per slice, 
since fluorescence intensity is greater for FITC-labeled proteins bound to their target than 
for FITC-labeled proteins in solution168. Total fluorescence was significantly lower for Aβ42-
containing clots (Figure 3.10C). These results demonstrate that Aβ42-modified fibrin binds 
less plasminogen, but they do not prove that Aβ is blocking plasminogen’s access to fibrin, 
since changes in fibrin fiber thickness may be an alternative explanation. To avoid the 
possible modification of fibrin fibers by Aβ42 during fibrin formation, I used an immobilized 
fibrin monolayer overlaid with Aβ or vehicle as a surface for plasminogen binding. Excluding 
Aβ42 from fibrin polymerization eliminates the influence of Aβ42 on fibrin thickness, and also 
changes the binding target for Aβ42 from fibrinogen to fibrin. The binding affinity of Aβ42 for 
pre-formed fibrin may be different (and possibly lower) than for fibrinogen due to 
conformational changes near the Aβ binding site on fibrinogen that accompany the 
fibrinogen-fibrin transition. Nonetheless, Aβ42 overlay of fibrin monolayers decreased the 
amount of plasminogen bound to fibrin (Figure 3.10D), suggesting that Aβ42 can inhibit 
plasminogen binding to fibrin by impeding its access to fibrin independently of fibrin fiber 




Figure 3.10. Aβ42 inhibits plasminogen binding to fibrin and plasmin generation. 
Fibrin clots were formed with FITC-plasminogen as described in methods, and 5 µm z-
stacks composed of 11 sections were acquired and projected two-dimensionally for control 
(A) and Aβ42-containing (B) clots. Images of 15 random sections from 3 separate clots were 
also acquired and used for quantification (insets show representative single sections). (A) 
Control clots formed with FITC-plasminogen show plasminogen fluorescence in the pattern 
of the fibrin network. (B) Clots formed with Aβ42 have less FITC-plasminogen fluorescence. 
(C) Fluorescence intensity relative to maximum intensity recorded was significantly lower 
(p=0.02) for Aβ42-containing clots. (D) Plasminogen binding to fibrin monolayers exposed to 
2 µM Aβ42 or vehicle was measured by ELISA and normalized to samples not containing 
plasminogen. Plasminogen binding was decreased in the presence of Aβ42 (p = 0.04). (E) 
Plasmin generation was measured by overlaying tPA, plasminogen, and chromogenic 
substrate Pefa-5329 on fibrin monolayers exposed to 2 µM Aβ42 or vehicle and recording 





To test whether the decrease in plasminogen binding translates to decreased plasmin 
generation, fibrin monolayers were exposed to Aβ42 or vehicle, and the rate of plasminogen 
activation by tPA was measured using chromogenic substrate Pefa-5329. Plasmin activity 
was decreased in fibrin monolayers that had been exposed to Aβ42 (Figure 3.10E). The 
activation of plasminogen by tPA was fibrin-dependent, since identical reactions in wells that 
did not contain fibrin monolayers produced negligible amounts of plasmin (not shown). This 
confirms that fibrin in the presence of Aβ is a weaker enhancer of plasminogen activation by 
tPA (as in Figure 3.7), but without the differences in clot structure as a confounding factor.  
3.10. Aβ42 overlaid onto pre-formed clots delays fibrinolysis 
I next tested whether Aβ42 can delay fibrinolysis independently of its effect on clot 
structure. Clots prepared without Aβ42, and therefore having normal structure, were overlaid 
with a solution containing Aβ or vehicle for 1 hour, after which the solutions were removed 
and the clot surfaces washed. The clots were then overlaid with a tPA solution to initiate 
fibrinolysis. Aβ42 overlay significantly delayed half-lysis of clots compared to control (Figure 
3.11A,B), indicating that Aβ-mediated alterations in clot structure are not necessary for 







Figure 3.11. Pre-formed clots overlaid with Aβ42 are resistant to lysis. (A) Pre-formed 
clots (prepared as described in methods) containing no Aβ were overlaid with 5 µM Aβ42 
(dashed line) or control buffer (solid line) for 1 hr, the overlays removed, and the clot 
surfaces washed. All clots were then overlaid with 10 nM tPA to initiate lysis. (B) Half lysis of 
clots that had been overlaid with Aβ was significantly delayed compared to control clots (p = 
0.012). (C-H) Confocal microscopy of clots using Alexa Fluor-488 labeled fibrinogen and 
HiLyte Fluor-555 labeled Aβ. (C,D) Normal clot overlaid with buffer. (E,F) Normal clot 
overlaid with 555-Aβ42 (3 µM) for 1 hr contained fibrin-bound Aβ42 (G,H). Normal clot 
overlaid with 555-Aβ(1-9)  (3 µM) for 1 hr did not show specific co-localization between fibrin 




I examined if the delay in lysis provoked by overlaid Aβ42 results from its ability to 
penetrate the clot and bind to fibrin after clot formation. Clots formed without Aβ42 were 
overlaid with Aβ42-555 and incubated for 1 hour. After removal of the overlay and washing, 
the interior of the clots was visualized. No structural alterations of the Aβ-overlaid fibrin 
network were found (Figure 3.11C,E). However, Aβ42-555 labeling of the fibrin fibers was 
observed (Figure 3.11F), indicating that Aβ had penetrated the clot and accumulated on the 
fibrin lattice. Overlays with Aβ(1-9)-555 did not lead to specific 555-labeling of fibrin, but 
produced diffuse fluorescence corresponding to non-specific penetration of Aβ(1-9)-555 into 
the clot (Figure 3.11H). The delay in lysis in these structurally normal clots could thus result 
from Aβ-mediated blockage of plasmin(ogen)’s access to fibrin (Figure 3.10).  
Taken together, these results show that generation of plasmin is slowed, and that 
plasmin-mediated degradation of clots is attenuated in clots formed with Aβ42. This occurs 
through Aβ42-mediated hindrance of plasmin(ogen)’s access to fibrin and from Aβ-induced 
tightening of the fibrin network, and not through the direct effect of Aβ42 on fibrinolytic 
enzyme activity. Inhibiting the binding between Aβ42 and fibrinogen could therefore 
normalize fibrin clot lysis and possibly reduce the prothrombotic phenotype observed in AD 
patients and mouse models.  
3.11. Aβ42 aggregation state: effects on clot structure fibrinolysis 
Aβ42 aggregates into oligomers, protofibrils, and fibrils, a process that may be 
accelerated in the presence of fibrin(ogen)125. To determine whether the aggregation state of 
Aβ42 modulates its effect on fibrin clot structure and fibrinolysis, preparations of Aβ42 with 
varying potential for aggregation were used. Aβ42 I31P is unable to form aggregates with 
beta-sheet structure152, a characteristic of Aβ fibrils. Incubation of Aβ42 I31P for 24 hours at 
37oC resulted in much less aggregated material by TEM compared to Aβ42 (Figure 3.12A,B). 
Aβ I31P was able to bind fibrinogen, as demonstrated by pulldown assay using biotinylated 
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fibrinogen FragD (Figure 3.3A) and via ELISA to fibrin monolayer (not shown). Unlike fibrin 
clots formed in the presence of Aβ42, clots formed in the presence of Aβ42 I31P were not 
characterized by clumps and a thinner network of fibers or differ in any other way from clots 
formed with vehicle (Figure 3.12D-F). Furthermore, clots formed in the presence of Aβ42 
I31P had similar susceptibility to lysis as clots formed with vehicle (Figure 3.12, G and H), 
suggesting that Aβ42 aggregates/structures need to attain a certain size threshold in order 
for their binding to fibrin(ogen) to affect clot structure and susceptibility to lysis.  
Unlike Aβ42, Aβ42 labeled with the fluorophore 555 Hylite Fluor (Aβ42-555) forms 
oligomers and protofibrils but does not assemble into fibrils following incubation (Figure 
3.12A,C). Aβ42-555 is able to bind to fibrin(ogen), as shown by the colocalization of the 
peptide with the fibrin network (Figure 3.12J) and pulldown assay (not shown). Clots formed 
in the presence of Aβ42-555 have a thinner network of fibrin than control clots but lack the 
clumps seen in clots formed with Aβ42 (Figure 3.12H,I). Furthermore, Aβ42-555-influenced 
clots are more resistant to fibrinolysis than control clots, which is not a function of the 







Figure 3.12. Aβ42 aggregation state differentially affects fibrin structure and lysis. (A) 
TEM of Aβ42 showing oligomers, protofibrils, and fibrils. (B) TEM of Aβ42 I31P mutant 
showing a lack of oligomers and fibrils. Monomers are too small to be visualized by EM. (C) 
TEM of 555-Aβ42 showing oligomers but no fibrils. (D-F) Fibrin clots prepared in the 
presence of vehicle (D), Aβ42 (E), or Aβ42 I31P (F). Fibrin fibers are shown in green. (G) 
Fibrinolysis is not delayed in the presence of Aβ42 I31P. (H-J) Fibrin clots prepared in the 
presence of vehicle (H) or 555-Aβ42 (I,J). Fibrin (green) is shown in H and I, while 555-Aβ42 
(red) is shown in J. (K) Fibrinolysis is delayed in the presence of Aβ42-555 but not Aβ(1-9)-




CHAPTER 4.  Aβ42 is prothrombotic via activation of the FXII-driven intrinsic 
coagulation pathway 
4.1. Aβ42 promotes thrombin generation in plasma  
A prothrombotic state may be achieved not only by decreased fibrinolysis, as described 
in Chapter 3, but also by over-activation of the coagulation cascade. To test if Aβ42 could 
promote coagulation, I quantified thrombin generation in human plasma using the Calibrated 
Automated Thrombogram method (CAT)144 in the presence of oligomeric Aβ42, a toxic 
assembly that correlates with disease severity169. The oligomeric composition of my Aβ42 
preparation (Methods 2.15) was confirmed by electron microscopy (Figure 4.1A). In the 
absence of exogenous activators, a small thrombin burst is detectable after a long lag period 
(Vehicle, Figure 4.1B-D). Addition of Aβ42 to platelet rich plasma promoted thrombin 
generation in a dose-dependent manner, as indicated by a shortening of the lag time to 
thrombin burst and an increase in peak height (maximum thrombin formed) (Figure 4.1B). A 
similar prothrombotic effect was observed in platelet poor plasma (Figure 4.1C), indicating 
that platelets are not required. However, Aβ42 had no effect in microparticle- and exosome-
free plasma prepared by ultracentrifugation (Figure 4.1D). Supplementing ultracentrifuged 
plasma with phospholipids restored Aβ42’s ability to trigger thrombin generation (Figure 
4.1D), indicating that the presence of phospholipid surfaces (found on platelets, 
microparticles, or exosomes) is required for Aβ42-mediated thrombin generation. The 
prothrombotic effect is specific to Aβ42, since amylin, another amyloid-forming peptide, 






Figure 4.1. Aβ42 triggers thrombin generation in human plasma. (A) Representative 
TEM image of Aβ42 oligomers used. (B-E) Real-time thrombin generation was measured by 
CAT. (B) Platelet rich plasma (PRP) was incubated with Aβ42 at concentrations indicated or 
kaolin (a known activator of thrombin generation). Lag time to thrombin generation was 
decreased and thrombin peak was increased in the presence of Aβ42 in a dose-dependent 
manner. (C) As in (B), except platelet poor plasma (PPP) was used. (D) Aβ42 had no effect 
in plasma lacking platelets microparticles, and exosomes (labeled as Microparticle Free 
Plasma). Addition of phospholipids (PL; 4 µM) restored Aβ42’s ability to trigger thrombin 
generation. (E) Lag time to thrombin generation was decreased and maximum peak height 
was increased in PPP with Aβ42 but not amylin. All experiments were performed in 




4.2. Aβ42-mediated thrombin generation is FXII-dependent  
Thrombin is generated through the activation of either the intrinsic (FXII-driven) or 
extrinsic (tissue factor; TF-driven) pathways of coagulation (Figure 4.2A). To determine 
which pathway is activated by Aβ42, CAT experiments were performed in the presence of 
either a FXIIa function blocking antibody145 (to block the intrinsic pathway), or with active 
site-inhibited factor VII (ASIS; to block the extrinsic pathway). The FXIIa antibody abolished 
Aβ42-induced thrombin generation (Figure 4.2B), whereas ASIS had no effect (Figure 4.2C), 
suggesting that Aβ42 is prothrombotic via the FXIIa-driven intrinsic coagulation pathway. 
The specificity of the FXIIa antibody to block FXIIa-mediated thrombin generation was 
confirmed by showing that it blocked thrombin generation initiated by kaolin, a known 
activator of FXII, but did not interfere with tissue factor (TF)-initiated thrombin generation. As 
expected, ASIS inhibited TF-initiated thrombin generation (not shown). 
To further examine the role of FXII in Aβ42-mediated thrombin generation, I analyzed 
the effect of Aβ42 in plasma obtained from an individual deficient in FXII, having no 
detectable plasma FXII antigen (Figure 4.2D inset). Aβ42 failed to trigger thrombin 
generation in FXII-deficient human plasma (Figure 4.2D, dashed curves). To examine the 
role of Aβ42 in a system where FXII is completely absent, I tested plasma from mice that do 
not express any FXII (FXII-/-). While Aβ42 promoted thrombin generation in WT mouse 
plasma, no effect was seen in FXII-/- mouse plasma (Figure 4.2E), corroborating results 
obtained from plasma in which FXIIa was blocked by antibody (Figure 4.2B) and from FXII-






Figure 4.2. Aβ42 promotes thrombin generation in a FXII-dependent manner. (A) 
Intrinsic and extrinsic pathways of coagulation. (B-E) Real-time thrombin generation was 
analyzed by CAT. (B) Aβ42-induced thrombin generation was blocked by a monoclonal 
antibody against FXIIa (4 µM), but not by IgG. (C) Aβ42’s enhancement of thrombin 
generation was not affected by the extrinsic coagulation pathway inhibitor ASIS (60 nM). (D) 
Thrombin generation was not enhanced in human plasma from a FXII-deficient individual in 
the presence of Aβ42. Deficiency of FXII in this plasma was confirmed by Western blot (WB; 
inset). Aβ42 had no effect when thrombin generation was triggered by 3 pM FXIa. (E) 
Thrombin generation was enhanced in WT mouse plasma but not FXII-/- mouse plasma in 
the presence of Aβ42. Mouse plasma contained 240 nM ASIS to block TF-mediated 
thrombin generation stemming from TF contamination during blood draw. ASIS does not 
affect Aβ42-mediated enhancement of thrombin generation (Figure 4.2C). All experiments 




Since FXII-deficient or -neutralized plasmas have normal levels of FXI, FIX, FX, FVII, 
and prothrombin, the results also indicate that thrombin generation is not driven through 
direct activation of any of these factors by Aβ42. However, it is possible that Aβ42 may 
potentiate these factors when they are in the activated state, low levels of which may be 
induced by minute FXII activation triggered by contact with the well surface or during 
sampling and storage (e.g. the background thrombin signal in Figure 4.1B-D). To address 
this possibility, thrombin generation in FXII-deficient human plasma was measured following 
addition of low levels of FXIa, which can activate the remaining members of the coagulation 
cascade (Figure 4.2A). Aβ42 had no effect on thrombin generation in plasma activated with 
FXIa (Figure 4.2D, solid curves), indicating that it does not enhance the activity of FXIa or 
any downstream factors. Furthermore, Aβ42 had no effect on thrombin generation in plasma 
from mice that have normal levels of FXII but do not express FXI (not shown), confirming 
that the pathway enhanced by Aβ42 involves FXIIa-mediated activation of FXI and not 
FXIIa-mediated activation of another substrate. 
4.3. Aβ42 oligomers trigger FXII-dependent FXI activation in vitro  
FXII undergoes autoactivation on negatively charged surfaces to generate FXIIa. Since 
autoactivation of FXII has only been shown with fibrillar Aβ and in the presence of ZnCl2121, I 
first determined that Aβ42 oligomers can bind FXII (Figure 4.3A, first panel) and directly 
induce FXII autoactivation (Figure 4.3B). Physiologically, contact system activation takes 
place in the presence of prekallikrein, which is activated by FXIIa to kallikrein, which in turn 
activates additional FXII, amplifying the reaction (feedback activation; Figure 1.2). Aβ42 
dose-dependently promoted FXII activation in the presence of prekallikrein (Figure 4.3C), as 
seen through the reduction of FXII zymogen levels (80 kDa) and the appearance of the 
heavy chain fragment of FXIIa (52 kDa).  
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The activation of FXI by FXIIa requires co-localization of the two factors on the activating 
surface. A pulldown assay revealed that Aβ42 binds both FXI and FXII (Figure 4.3A), 
indicating that Aβ42 oligomers are a surface capable of co-localizing FXII and FXI, thereby 
facilitating FXIIa-mediated FXI activation. Indeed, Aβ42 led to robust FXIIa-dependent FXIa 
generation compared to vehicle in the absence (Figure 4.3D) and presence (Figure 4.3E) of 
prekallikrein, indicating that FXII activated by Aβ42 is capable of cleaving its substrate FXI. 
Interestingly, the relationship between the concentration of Aβ42 oligomers and the level of 
FXII-dependent FXI activation was not linear. FXI activation peaked at ~500 nM Aβ42, with 
further increases to Aβ42 concentration resulting in diminished FXI activation (Figure 4.3F). 
This behavior is consistent with a template-like mechanism for this process, where there is 
an optimal concentration of Aβ42 that allows FXII and FXI to bind the same Aβ42 molecule. 
Too much Aβ42 separates FXII and FXI to different Aβ42 molecules, resulting in less 
intermolecular interaction and decreased activation. 
Previously, FXIIa-dependent FXI activation and procoagulant effects were not detected 
when Aβ42 was tested as an activator122. The main difference between our experiments is 
that Maas et al. used “amorphous aggregates” of Aβ42 with the Dutch mutation (E22Q) 
instead of the oligomeric Aβ42 tested here. This discrepancy prompted me to analyze the 
ability of Aβ42 in different states of aggregation as well as other Aβ variants to trigger FXII-
dependent FXI activation. My results demonstrate that Aβ42 oligomers had a much greater 
ability to trigger FXII-dependent FXI activation compared to freshly dissolved Aβ42 and 
Aβ40 (Figure 4.3G,H). No FXI activity was detected in the presence of Aβ42 fibrils (Figure 
4.3G). However, even when the most active (oligomeric) form of Aβ42 Dutch was tested, it 
was substantially less potent than oligomeric Aβ42 in stimulating FXII-dependent FXI 
activation (Figure 4.3I), indicating that the discrepancy between our results is a function of 
the use of Aβ42 Dutch in the Maas et al. study.  
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Figure 4.3. Aβ42 promotes FXII-dependent FXI activation in vitro. (A) Western blot 
showing results of pulldown assay with biotinylated Aβ42 oligomers and purified FXII (left 
panel) or FXI (right panel). Western blots were probed with anti-FXII and FXI antibodies, 
respectively. (B) Aβ42 triggered autoactivation of FXII by chromogenic substrate assay. (C) 
In the presence of both FXII and prekallikrein, Aβ42 dose-dependently promoted activation 
of FXII as seen through the reduction of FXII zymogen level at 80 kDa and appearance of 
the FXIIa heavy chain at 52 kDa. Dextran sulfate 500 kDa (DS500) and kaolin were used as 
positive controls. (D) Aβ42 triggered FXII-dependent FXIa generation by chromogenic 
substrate assay. The signal was not due to non-specific cleavage of chromogenic substrate 
by FXIIa, or by autoactivation of FXI, as seen in controls where FXII or FXI were omitted. (E) 
FXI activation can be seen through the appearance of the 50 kDa FXIa heavy chain band 
following incubation of FXII, FXI, prekallikrein (PPK), and HK with Aβ42 or kaolin. (F) FXII-
dependent FXI activation was analyzed with various concentrations of Aβ42 oligomers by 
chromogenic substrate assay and absorbance after 2 hours analyzed. Significance is with 
respect to vehicle (0 nM Aβ42). (G) Aβ42 oligomers were more potent in promoting FXII-
dependent FXI activation than freshly dissolved Aβ42. Aβ42 fibrils had no effect. (H) Aβ42 
oligomers were more potent than Aβ40 oligomers in promoting FXII-dependent FXI 
activation. (I) Aβ42 oligomers (TEM image, top inset) promoted FXII-dependent FXI 




4.4. Aβ42 oligomers trigger FXII-dependent FXI activation in plasma 
To investigate the relevance of FXII-mediated FXI activation by Aβ42 to a more complex 
environment, I examined this process in human plasma. Biotinylated Aβ42, but not 
biotinylated amylin, was able to bind FXII in plasma as shown by pulldown assay (Figure 
4.4A), demonstrating that the Aβ42-FXII interaction is specific and occurs in the presence of 
plasma proteins. This interaction leads to FXII activation, since plasma incubated with Aβ42 
had decreased FXII zymogen and increased FXIIa heavy chain compared to incubation with 
vehicle (Figure 4.4B). While Western blotting cannot sensitively detect FXI activation, 
plasma FXIa can be measured by quantifying FXIa-inhibitor complex formation, since FXIa 
generated in plasma is rapidly bound by inhibitors170. Incubation of plasma with Aβ42 but not 
Aβ42 Dutch resulted in significantly increased levels FXIa-C1 inhibitor (C1inh) complex than 
when plasma was incubated with vehicle (Figure 4.4C; p <0.001). The activation of FXI by 
Aβ42 was FXII-dependent, since incubation of FXII-deficient plasma with Aβ42 did not result 
in increased FXIa-C1inh complex formation. Because multiple inhibitors neutralize FXIa in 
plasma, I tested whether FXIa generated in plasma following Aβ42-mediated activation of 
FXII is bound by other inhibitors in addition to C1inh. The level of FXIa-α1 antitrypsin (α1AT) 
complex in plasma following activation with Aβ42 was also increased relative to vehicle 









Figure 4.4. Aβ42 promotes FXII-dependent FXI activation in plasma. (A) Western blot 
demonstrating that biotinylated Aβ42 oligomers bind FXII in human plasma. (B) Aβ42 
oligomers incubated with human plasma lead to FXII activation. (C) ELISA measuring FXIa-
C1inh complex formation in normal and FXII-deficient human plasma. Oligomers of Aβ42 
but not Aβ42 Dutch promoted the formation of more FXIa-C1inh than vehicle (p <0.001) (D) 
ELISA measuring FXIa-α1AT complex formation in normal human plasma. Aβ42 oligomers 
resulted in increased complex formation compared to vehicle (p <0.0001). Results are 




4.5. Levels of FXI zymogen and C1inh are decreased in AD patient plasma  
In vivo, increased activation of plasma FXI can be detected as decreased plasma FXI 
zymogen levels, often observed in disease states accompanied by FXI activation171-173. 
Decreased plasma FXI zymogen levels could reflect continuous consumption of FXI due to 
its activation and clearance. Levels of FXI zymogen normalized to transferrin loading control, 
plasma levels of which are not altered in AD174, were analyzed by Western blot in two sets of 
AD patient and non-demented control (ND) plasmas obtained from two AD tissue banks 
(see Methods 2.21). Ten AD and 10 ND cases in Group 1 were age-, gender-, and ApoE 
genotype-matched, while 10 AD and 10 ND cases in Group 2 were age-matched. AD 
plasma had decreased levels of FXI zymogen compared to ND plasma in both Group 1 
(0.43 ± 0.07 vs. 0.69 ± 0.20, p = 0.008; Figure 4.5A,B) and Group 2 (0.85 ± 0.25 vs. 1.44 ± 
0.28, p = 0.0003, p <0.0001; Figure 4.5D,E). If AD plasma FXI levels are decreased due to 
its activation and clearance, levels of its main inhibitor C1inh170 would also be expected to 
decrease. Indeed, C1inh levels were decreased in AD vs. ND plasma in both Group 1 (0.59 
± 0.20 vs. 1.33 ± 0.43, p = 0.0008; Figure 4.5A,C) and Group 2 (1.0 ± 0.12 vs. 1.2 ± 0.18, p 
= 0.012; Figure 4.5D,F), suggesting its consumption due to increased activation of FXIIa, 
kallikrein, and/or FXIa.  
Activation of the intrinsic pathway of coagulation would be expected to result in 
increased thrombosis and fibrin formation. Indeed, plasma fibrin levels (as determined by 
monoclonal antibody 59D8 against fibrin175) were elevated in AD patients from Group 2 
compared to controls (0.97 ± 0.17 vs. 0.74 ± 0.15, p = 0.009; Figure 4.5G,H). Levels of fibrin 
were inversely correlated with FXI levels (r = -0.46, p = 0.04; Figure 4.5I), suggesting that 
activation and subsequent clearance of FXI results in thrombin generation and fibrin 
formation. In Group 1, there was a non-significant trend toward increased fibrin levels in AD 
plasma (not shown), which could be due to differences in blood draw and anticoagulation 
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methods between the groups (see Methods 2.21). Another possible explanation stems from 
the more advanced disease stage of AD patients in Group 1 compared to Group 2 as 
determined by clinical dementia rating score (2.0 ± 1.1 vs. 1.0 ± 0.6, p = 0.028). Since 
Group 1 patients are likely to have been exposed to FXI activation for longer due to more 
advanced disease, the fibrin formed may have been progressively deposited, thereby 
depleting soluble fibrin monomers from plasma.  
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Figure 4.5. AD patient plasma has lower levels of FXI and C1inh. (A) Non-reducing 
Western blot analysis of FXI, C1inh, and transferrin loading control in plasma of 10 AD 
patients and 10 ND controls from Group 1. Lanes loaded with FXI purified protein (FXI) and 
FXI-deficient human plasma (FXI-def) show that the band just above the FXI band is non-
specific. (B) FXI levels normalized to transferrin were lower in AD than ND plasma (p=0.008). 
(C) C1inh levels were lower in AD than ND plasma (p = 0.0008). (D) Levels of FXI, C1inh, 
and transferrin were analyzed in 10 AD and 10 ND plasmas from Group 2. (E) FXI levels 
were lower in AD than ND plasma (p = 0.0003). (F) C1inh levels were lower in AD than ND 
plasma (p = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 
10 AD and 10 ND plasma samples from Group 2 using antibody 59D8 specific for fibrin beta 
chain175. (H) Fibrin levels were increased in AD plasma compared to control (p = 0.009). (I) 







CHAPTER 5. Aβ42 is proinflammatory via activation of FXII in the AD circulation and 
brain parenchyma 
5.1. Aβ42 promotes FXII-dependent kallikrein-kinin system activation in plasma  
I have shown that Aβ42-mediated activation of FXII can result in FXI activation and 
thrombin generation, and that this may occur in AD patient plasma (Chapter 4). Thrombin 
generation is not the only possible outcome of Aβ-mediated FXII activation, since FXIIa can 
also activate the proinflammatory kallikrein-kinin system (Figure 1.2). Indeed, Aβ has been 
shown to trigger FXII-dependent kallikrein generation and HK cleavage in vitro121,122,176, and 
increased cleavage of HK occurs in AD patient CSF176. However, activation of the FXII-
driven kallikrein-kinin system has not been shown with oligomeric Aβ42 or in AD patient 
plasma.  
Since Aβ-mediated contact activation appears to be sensitive to small changes in the 
makeup of Aβ preparations (Figure 4.3), I first confirmed the ability of my preparation of 
oligomeric Aβ42 to trigger FXII-dependent prekallikrein activation in a purified protein 
system (Figure 5.1A). Prekallikrein activation in the presence of Aβ42 was also observed in 
normal plasma, as seen through the reduction in 86 kDa prekallikrein zymogen levels 
(Figure 5.1B). Incubation of plasma with Aβ42 generated functional kallikrein that cleaved its 
substrate HK in a dose-dependent manner, seen as diminished signal intensity of single 
chain (uncleaved) HK bands at 120 kDa (Figure 5.1C). Decreases in uncleaved HK levels 
were accompanied by the appearance of cleaved HK fragments: the light chain band 
migrating at 56 kDa and an additional 45 kDa band representing a degradation product of 56 
kDa HK light chain. Aβ42-initiated HK cleavage in plasma was FXII-dependent, since Aβ42 









Figure 5.1. Aβ42 triggers FXII-dependent prekallikrein activation and HK cleavage. (A) 
Aβ42 (3 µM) promoted kallikrein generation in the presence of FXII (10 nM) and prekallikrein 
(PPK; 10 nM) as measured by chromogenic substrate Pefachrome PK. The specificity of 
Pefachrome PK for detecting kallikrein and not FXIIa activity was confirmed by testing 10 
nM FXIIa (maximum amount of FXIIa generated in the assay) with no prekallikrein, which 
did not result in any substrate cleavage (not shown). (B) Aβ42 (20 µM) and kaolin (100 
µg/ml) promoted PPK activation in human plasma. (C) Aβ42 promoted HK cleavage in a 




5.2. Increased contact system activation in AD patient plasma (Group 1) 
If activation of the FXII-driven kallikrein-kinin system by Aβ occurs in vivo, AD patient 
plasma may show evidence of this process. Plasma from AD patients and controls was 
obtained from two tissue banks (Methods 2.21). Samples from the University of Kentucky 
Sanders-Brown Center on Aging (Group 1) consisted of 18 AD and 11 ND samples matched 
with respect to age and gender (Table 1). The extent of dementia in these individual had 
been assessed using Clinical Dementia Rating (CDR) scores, where 0 = no dementia and 3 
= severe dementia177, as well as Mini Mental State Examination (MMSE) scores, where 30 = 
no dementia and 0 = severe dementia178. At the time of blood draw, Group 1 AD cases had 
an average CDR score of 1.6 ± 1.3 (range 0-3) and an average MMSE score of 16.5 ± 9.6 
(range 0-30), corresponding to moderate dementia. The presence of CDR 0 and MMSE 30 
individuals in this group can be attributed to the fact that several (n = 3) were diagnosed with 
MCI or AD after blood draw. Upon autopsy, the majority of Group 1 AD cases (77.8%) were 
Braak stage 5 or 6, corresponding to severe dementia (Table 1)179.  
Plasma FXII activation in Group 1 AD patients and ND controls was analyzed under 
reducing conditions, with results reported after normalization to transferrin loading control. 
Cleavage of the FXII zymogen (80 kDa) and the appearance of a heavy chain band at 52 
kDa were detected in 13 of 18 AD plasmas and 2 of 11 ND plasmas in Group 1 (Figure 
5.2A). Levels of the 52 kDa heavy chain fragment, the generation of which typically 
corresponds to FXII activation, were higher in AD than in ND cases (0.47 vs. 0.07, p=0.029; 




Table 5.1. Characteristics of AD and ND cases from Group 1 
 AD (18) ND (11) 
Gender (% Male) 61 64 
Mean age at blood draw (years; SD) 82.4 (9.1) 82.5 (6.3) 
Mean CDR at blood draw (score; SD) 1.56 (1.28) 0 (0.2) 
Mean MMSE at blood draw (score; SD) 16.5 (9.6) 28.5 (1.5) 
CERAD (%)   
None 0 100 
B 27.8 0 
C 72.2 0 
Braak stage (%)   
0-2 16.7 100 
3-4 5.6 0 
5-6 77.8 0 
History of (%)   
Hypertension 50 63.6 
Atrial Fibrillation 5.6 18.2 
Stroke 27.8 0 
Diabetes 5.6 18.2 
Hypercholesterolemia 38.5# 45.5 
Myocardial Infarction 11.1 27.3 
# History of hypercholesterolemia data was available for only 13 AD cases. 
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Figure 5.2. Contact system activation in AD patient plasma from Group 1. (A) Western 
blot analysis of FXIIa and transferrin loading control in plasma of 18 AD patients and 11 ND 
controls from Group 1 (representative samples shown). FXII zymogen is observed at 80 kDa 
and the αFXIIa heavy chain at 52 kDa. Lane loaded with FXII-deficient human plasma (FXII-
def) shows that the bands just below and above the FXIIa band are non-specific. (B) FXIIa 
levels normalized to transferrin were higher in AD (p = 0.029) than ND plasma. When AD 
cases with a history of stroke (n = 5) were excluded from the analysis, FXIIa levels in AD 
with stroke-excluded cases (AD SE) remained significantly higher than in ND plasma (p = 
0.018). (C) Western blot analysis of HK in representative samples: uncleaved HK is 
observed at 120 kDa, HK light chain at 56 kDa, and light chain fragment at 45 kDa. (D) 
Uncleaved HK levels normalized to transferrin were significantly lower in AD (p <0.0001) 
than ND plasma. When AD cases with a history of stroke (n = 5) were excluded from the 
analysis, uncleaved HK levels in AD with stroke excluded cases (AD SE) remained 
significantly lower than in ND plasma (p = 0.0002). Red points represent individuals who 
developed cognitive decline at least one year after blood draw. (E) Kallikrein-like activity was 
higher in AD plasma compared to ND (p = 0.0006). (F) Kallikrein-like activity was correlated 
with HK levels (r  = 0.81, p <0.0001). (G) HK levels normalized to transferrin were higher in 
both individuals with CERAD score B (p = 0.003) and CERAD score C (p <0.0001) than in 
individuals with CERAD score 0. Samples were analyzed 3 separate times with similar 
results. Results are presented as vertical scatter plots with medians, with statistical 
significance determined using the Mann-Whitney test for two-group comparisons and the 





Activation of FXII may occur in conjunction with co-morbidities present in AD patients 
that are absent in controls. However, records of self- or caregiver-reported medical 
conditions indicate that AD cases did not have higher levels of hypertension, 
hypercholesterolemia, diabetes, myocardial infarction, or atrial fibrillation than controls 
(Table 1), arguing against a role for these co-morbidities in the increased FXIIa levels 
observed in AD patient plasma. Interestingly, history of stroke was found in 5 of 18 (almost 
30%) of AD cases, but was absent in ND cases. Stroke is mediated by thrombosis and/or 
vessel rupture, both of which generate surfaces for FXII activation such as 
polyphosphates180 and RNA181. However, excluding AD cases with history of stroke did not 
substantially change the FXIIa levels in AD and ND groups (0.47 vs. 0.07 respectively, p = 
0.018; Figure 5.2B).  
The presence of FXIIa in AD patient plasma in Group 1 (Figure 5.2A) was accompanied 
by HK cleavage (decreased intensity of bands at 120 kDa; Figure 5.2C). AD plasma as a 
group had much lower levels of uncleaved HK than ND plasma (0.01 vs. 1.19, p <0.0001; 
Figure 5.2D), even when AD cases with history of stroke were excluded (0.01 vs. 1.19, p = 
0.0002; Figure 5.2D). Decreases in uncleaved HK levels were accompanied by the 
appearance of cleaved HK fragments at 56 kDa and 45 kDa. Because HK cleavage 
products are rapidly degraded182, samples with high levels of HK cleavage did not 
necessarily have proportionally higher levels of HK light chain, making quantification of the 
HK breakdown products uninformative. Interestingly, some samples (e.g. AD1 and AD2) that 
did not have detectable FXIIa showed evidence of HK cleavage, demonstrating that HK 
cleavage is a more sensitive indicator of contact activation than FXII activation.  
To determine whether the reduction in uncleaved HK levels observed by Western blot is 
a result of contact system activation, I measured the activity of plasma kallikrein, the 
enzyme responsible for HK cleavage. Kallikrein-like activity, measured by chromogenic 
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substrate assay, was higher in AD vs. ND plasma (40.9% vs. 4.5% of fully activated plasma, 
p = 0.0006; Figure 5.2E) and correlated with HK cleavage as detected by Western blot (r = 
0.81, p <0.0001; Figure 5.2F). Since kallikrein generation is triggered by FXIIa, this result 
also indicates that FXII cleavage detected by Western blot represents FXII activation.  
When HK levels were plotted as a function of CERAD score (a measure of Aβ plaque 
pathology in the brain on autopsy: 0 = normal brain; B = probable AD; C = definite AD147), 
plasma from individuals with a CERAD score of 0 had higher levels of uncleaved HK 
compared to plasma from individuals with a CERAD score of B (1.19 vs. 0.01, p <0.05) or C 
(1.19 vs. 0.01, p <0.001) (Figure 5.2E). The fact that HK cleavage is apparent in the plasma 
of individuals with CERAD B and does not increase further in those with CERAD C suggests 
that FXIIa-driven inflammation begins early in disease progression and is mostly developed 
by the time individuals reach CERAD B status. The idea that HK cleavage is an early event 
in AD is also suggested by its presence in plasma from 3 individuals who were cognitively 
normal at time of blood draw but went on to develop cognitive impairment (red points in 
Figure 5.2D). 
5.3. Increased contact system activation in AD patients plasma (Group 2) 
Samples from the Washington University Knight Alzheimer’s Disease Research Center 
(Group 2) consisted of 10 AD and 10 ND samples matched with respect to age (Table 2). 
AD cases in Group 2 had an average CDR score of 1.0 ± 0.6 at the time of blood draw, with 
the majority (80%) being CDR 0.5 or 1 (Table 2), corresponding to very mild to mild 
dementia177. Group 2 individuals are still living and therefore Braak stages and CERAD 
scores are not available.  
While FXIIa was not detected in AD or ND plasma from Group 2 (not shown), uncleaved 
HK levels were lower in AD than ND (0.59 vs. 0.85; p <0.0001; Figure 5.3A,B). Kallikrein-like 
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activity was also increased in AD plasma from Group 2 (1.2% vs. 0.96% of fully activated 
plasma, p = 0.03; Figure 5.3C), corroborating the decreased levels of uncleaved HK seen by 
Western blot.   
Levels of CSF Aβ42, total tau (tau), and phosphorylated tau (p-tau) in Group 2 were 
available from the Washington University Alzheimer’s Disease Research Center. Decreased 
CSF Aβ42 levels are thought to be the earliest CSF marker of incipient AD, appearing as 
early as ~15 years prior to onset of symptoms and remaining low as disease progresses, 
while CSF tau and p-tau levels (related to neurofibrillary tangle formation and 
neurodegeneration) begin to rise closer to the appearance of cognitive decline (reviewed in 
183). We therefore performed correlation analyses for these CSF biomarkers and uncleaved 
HK levels. Levels of uncleaved plasma HK were positively correlated with CSF Aβ42 (r = 
0.63; p = 0.003; Figure 5.3C), consistent with increased HK cleavage in the plasma of 
individuals with lower CSF Aβ42. Uncleaved plasma HK did not correlate with CSF tau (r = -
0.11; p = 0.64; Figure 5.3D) or p-tau (r = -0.25; p = 0.28; Figure 5.3E), suggesting that 
increased HK cleavage may be an early event in AD progression that precedes substantial 
changes to neuronal injury markers.  
Undetectable FXIIa and less dramatic HK cleavage in Group 2 than Group 1 may stem 
from the earlier disease stage of Group 2 cases (CDR score Group 2, 1.0 ± 0.6 vs. Group 
1,1.6 ± 1.3) and from differences in blood collection. While I show that the degree of contact 
system activation may increase with disease progression (Figure 5.3D), the method of blood 
collection appears to also play a role, since ND plasma in Group 2 had lower kallikrein 








Table 5.2. Characteristics of AD and ND cases from Group 2 
 AD (10) ND (10) 
Gender (% Male) 30 50 
Mean age at blood draw (years; SD) 73.6 (5.8) 70.5 (3.9) 
Mean CDR at blood draw (score; SD) 1.0 (0.6) 0 (0) 
CDR (%)   
              0 0 100 
              0.5 40 0 
              1 40 0 




Figure 5.3. Contact system activation in AD patient plasma from Group 2. (A) Western 
blot analysis of HK and transferrin loading control in plasma of 10 AD patients and 10 ND 
controls from Group 2. (B) Uncleaved HK levels normalized to transferrin were significantly 
lower in AD (p <0.0001) compared to ND plasma. (C) Kallikrein-like activity was higher in AD 
plasma compared to ND (p = 0.03). (D) Levels of CSF Aβ42, which decrease with AD, were 
positively correlated with uncleaved HK levels (r = 0.63, p = 0.003). (E) Levels of CSF tau, 
which increase with AD, were not correlated with uncleaved HK levels (r = -0.11, p = 0.64). 
(F) Levels of CSF p-tau, which increase with AD, were not correlated with uncleaved HK 
levels (r = -0.25, p = 0.28). Samples were analyzed 3 separate times with similar results. 
Results are presented as vertical scatter plots with medians, with statistical significance 
determined using the Mann-Whitney test. 
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5.4. Blood draw method and detection of contact system activation 
In Group 1, blood was drawn into plastic heparinized Vacutainer tubes via vacuum, while 
Group 2 blood was drawn into EDTA-coated syringes via aspiration. Heparin can promote 
contact system activation in a purified protein system184 and in plasma diluted to 30%185, but 
not in plasma diluted to 90%186, arguing against heparin-mediated activation of undiluted 
blood during collection. On the other hand, EDTA is a Zn++ chelator and may therefore 
prevent ongoing contact activation after blood collection, resulting in detection of less FXIIa 
and uncleaved HK in Group 2. To test these possibilities, I evaluated the activation potential 
of blood from WT mice collected into heparin or EDTA (in collaboration with Zu-Lin Chen in 
the Strickland laboratory). Both EDTA- and heparin-anticoagulated plasma treated with the 
FXII activator dextran sulfate had comparably decreased levels of uncleaved HK (Figure 
5.4), indicating that heparin-mediated promotion or EDTA-mediated inhibition of ex-vivo FXII 
activation cannot explain the differences between Groups 1 and 2. However, the possibility 
remains that long-term storage of frozen plasma with EDTA vs. heparin could lead to 
differences in ex-vivo contact activation.  
Another possible explanation is that collection of blood into Vacutainer tubes is more 
likely to trigger FXII activation compared to slower blood draw into syringes (personal 
communication, Thomas Renné; Karolinska Institute). Indeed, plasma collected into 
Vacutainer tubes (with vacuum) has increased FXII-driven thrombin generation187 and 
earlier clot formation188 compared to blood drawn into S-Monovette tubes, which employ a 
syringe-like mechanism. Thus, blood draw methods used for Group 1 may have resulted in 
ex-vivo amplification of smaller differences in contact factor activation present in vivo, which 
did not occur in Group 2. 
It is important to note that there are limitations to my analysis of AD patient and ND 
control plasma inherent to the discontinuous chain of custody of the samples and potential 
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variability in sample storage, which could both play a role in ex-vivo activation of plasma 
proteins. While storage times were similar between AD and ND samples in Group 2, Group 
1 AD samples were (on average) stored for a longer time than ND samples. However, 
excluding some samples (AD = 3; ND = 3), and thereby equalizing average storage times 






Figure 5.4. Blood draw into EDTA or heparin does not affect ex-vivo contact activation. 
Blood from C57Bl/6 mice (n = 3) was drawn with EDTA or heparin anticoagulants as 
described in Methods 2.24. Plasma was activated with dextran sulfate (DXS), 0.1 µg/ml final 
concentration, or vehicle for 20 min at 37°C, and reactions stopped with reducing sample 
buffer. (A) Western blot analysis of plasma with an antibody against mouse HK (mHK). 
Mouse plasma contains mHK and mHK-∆D5 (mHK lacking domain 5)189, observed at ~110 
kDa and 82 kDa, respectively. (B) Uncleaved (sum of both mHK and mHK-∆D5 bands) is 
decreased in samples activated with DXS compared to vehicle in both EDTA and heparin 




5.5. Contact system activation in AD mice and in WT mice injected with Aβ42 
AD patients are a heterogeneous population with various disease etiologies and 
comorbidities. To analyze HK cleavage in a more homogeneous model, we examined 
plasma from the Tg6799 mouse model of AD, in which AD pathology is driven by the 
overexpression of human Aβ142 (hereafter referred to as AD mice; mouse experiments were 
done in collaboration with Zu-Lin Chen). Since detection of FXIIa by Western blot in mouse 
plasma is technically challenging given the poor ability of antibodies to recognize murine 
FXIIa fragments (not shown), we focused on HK cleavage as a marker of contact system 
activation. Compared to non-transgenic wild type littermate controls (WT), AD mice had 
decreased levels of uncleaved HK (2.0 vs. 1.6, p = 0.0012; Figure 5.5A,B). These data 
corroborate HK cleavage in human AD patient plasma and also support the idea that the 
increased HK cleavage in AD patient plasma is related to Aβ-driven AD pathology and not to 
comorbidities present in AD patients.  
We next investigated whether the increased HK cleavage found in AD patient and 
mouse model plasma could be mediated by Aβ42, an aggregation-prone, negatively-
charged peptide. To control for non-specific effects, scrambled Aβ42 as well as amylin, 
another aggregating peptide, were used. Peptide preparations were shown by TEM to be 
composed of similar sized structures (Figure 5.5C). Incubation of Aβ42 but not scrambled 
Aβ42, amylin, or vehicle with WT mouse plasma resulted in HK cleavage (not shown), 
confirming results obtained with human plasma121,123. Wild type (WT; C57BL/6) mice were 
then intravenously injected with the same peptides or vehicle. Plasma from mice injected 
with Aβ42 but not scrambled Aβ42 or amylin had decreased levels of uncleaved HK (2.8 ± 
0.8 vs. 4.5 ± 1.0, p <0.01; Figure 5.5D,E) and increased kallikrein-like activity (73.0 ± 38.2% 
vs. 4.9 ± 1.9% of fully activated plasma, p <0.001; Figure 5.5F) compared to plasma from 
mice injected with vehicle. The presence of Aβ42 in the blood of injected mice was 
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confirmed by ELISA (17.1 ± 9.0 ng/ml in Aβ42-injected mice compared to undetectable 
levels in vehicle-injected mice; lower limit of detection = 0.0156 ng/ml; Figure 5.5G). Aβ42-
mediated activation of the contact system in vivo (as determined by kallikrein activity in 
plasma) was both dose (r = 0.92, p <0.0001; Fig. 5.5H) and FXII-dependent, since injection 
of Aβ42 into FXII-/- mice did not result in increased kallikrein activity (Fig. 5.5I). Our 
combined results indicate that circulating Aβ42 functions as a FXII contact activator capable 
of triggering kallikrein activity and HK cleavage in vivo, and support the hypothesis that 
increased HK cleavage in AD patient and mouse model plasma is due to Aβ42-mediated 
FXII activation.  
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Figure 5.5. Contact system activation in plasma from an AD mice and from wild type 
mice injected with Aβ42. (A) Plasma from AD mice (n = 7) and littermate controls (WT; n = 
7) was analyzed by Western blot with an antibody against mHK; representative lanes shown.
(B) Levels of uncleaved mHK (sum of both mHK and mHK-∆D5 bands) normalized to 
transferrin were lower in AD than WT mice (p = 0.0012). (C) Representative TEM images of 
Aβ42, scrambled (scr) Aβ42, and amylin used for injections. Scale bar = 100 nm. (D) 
Representative lanes from blot probed with an antibody against mHK light chain showing 
C57BL/6 mice injected with vehicle, Aβ42, Aβ42 scr, or amylin. (E) The level of uncleaved 
HK normalized to transferrin was significantly lower (p <0.001) in mice injected with Aβ42  
than in vehicle-, Aβ42 scr-, or amylin-injected mice. (F) Kallikrein activity as measured by 
chromogenic substrate was increased in plasma from mice injected with Aβ42 but not Aβ42 
scr or amylin compared plasma from mice injected with vehicle (p <0.001). (G) Plasma Aβ42 
levels in C57BL/6 mice injected with Aβ42 were significantly higher than in mice injected 
with vehicle (p = 0.001). In mice injected with vehicle, levels of Aβ42 were below the 
detection limit of the ELISA (0.0156 ng/ml). (H) The dose of Aβ42 (0, 3, 6, or 9 mg/kg Aβ42) 
injected into WT mice (n = 4 per dose) correlated with kallikrein activity levels in plasma (r = 
0.92, p <0.0001). (I) Kallikrein activity was increased in WT (n = 4 per group; p <0.01) but 
not in FXII-/- mice injected with 6 mg/kg Aβ42 (n = 6 per group). Results are presented as 
vertical scatter plots with medians for panels B, G, and I, and with means for panels E and F, 
with statistical significance determined using the Mann-Whitney test for panels B and G, 







5.6. Contact system activation in AD brain parenchyma  
Activation of FXII by Aβ42 may occur not only in the circulation, but also in the brain 
parenchyma, where many components of the contact activation system are found190-194. 
Evidence of activation of these systems in AD is limited to increased plasma kallikrein 
activity in brain parenchyma193 and elevated levels of cleaved HK in CSF176. However, the 
presence and cleavage of HK in the AD brain parenchyma has not been investigated.  
Two mouse models of AD (TgCRND8 and Tg6799, see Methods 2.17 for details) were 
used to analyze contact system activation in the brain parenchyma as a function of age and 
hence disease progression. Marta Cortes-Canteli from the Strickland laboratory provided 
brain tissue and homogenates for all experiments described below. FXII was detected in 
both TgCRND8 and Tg6799 but not WT littermate control brains by immunofluorescence 
(Figure 5.6A; representative images from 35 week old Tg6799 mice and littermate controls 
probed with two anti-FXII antibodies are shown). FXII immunoreactivity surrounded Aβ 
immunoreactive regions in a halo-like pattern (Figure 5.6A), suggesting that FXII interacts 
with Aβ and corroborating results in AD patient brains190. The co-localization of FXII and Aβ 
was detected at 16 weeks of age in the TgCRND8 model (Figure 5.6B), around the time 
cognitive dysfunction first begins to appear, suggesting that FXII presence in the brain is not 
a consequence of late-stage disease. The presence of FXII in the brain at earlier time points 
has not yet been analyzed. Whether the FXII detected is produced locally or is a result of 
plasma protein extravasation across the BBB is unclear, although the presence of diffuse 
FXII immunoreactivity in WT brains (WT panels in Figure 5.6A,B) together with previous 
identification of FXII mRNA in the brain190,192 argues for local production. 
Co-localization between Aβ and FXII suggests that contact activation occurs in AD 
mouse model brains, which could result in bradykinin release from HK. While no HK was 
detected by Western blot in TgCRND8 (AD) or littermate control (WT) brains at 4- and 15 
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weeks (Figure 5.6C), increased HK levels were found in 58- and 82 week old AD vs. WT 
brains (Figure 5.6D, p <0.01 at 58 weeks, p <0.001 at 82 weeks). It is possible that 
differences in brain HK levels exist at or before 15 weeks, but that the antibodies used are 
not sufficiently sensitive to detect them. The presence of HK in AD mouse brain was 
confirmed by HK immunofluorescence, where it also co-localized with regions of Aβ 
accumulation (not shown). When the same samples were analyzed under reducing 
conditions (which separate the heavy and light chains of cleaved HK, clearly demonstrating 
HK cleavage), no signal was detected in AD or WT mice at any age. This suggests that the 
HK detected under non-reducing conditions represents cleaved HK, light chain fragments of 
which are rapidly degraded under reducing conditions (see for example the low level of HK 
light chain fragment in lane AD10, Figure 5.3C; when that blot is run under non-reducing 




Figure 5.6. FXII and HK in AD mouse model brain. (A) Representative confocal 
microscopy images of cortex from 35 week old Tg6799 (AD) and littermate control (WT) 
mice stained with antibodies against Aβ (green) and FXII (red – two different antibodies 
shown). DAPI staining is in blue. (B) Representative confocal microscopy images of cortex 
from 16 week old TgCRND8 (AD) and littermate control (WT) mice stained with antibodies 
against Aβ (green) and FXII (red). (C) Non-reducing Western blot analysis of soluble fraction 
from whole brain homogenates of TgCRND8 (AD) or littermate control (WT) mice at different 
ages (n = 3 for each group). Blots were probed with antibodies against mouse HK and 
tubulin as loading control. Under non-reducing conditions, mHK and mHK-∆D5 migrate 
together. (D) Levels of HK normalized to tubulin were increased in AD vs. WT mice at 58- (p 
<0.01) and 82 weeks (p <0.001) by 2-way ANOVA with Bonferroni post-test.  
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5.7. HK accumulation and cleavage in AD patient brain parenchyma  
The presence and cleavage of HK in human AD brain was analyzed in brain tissue from 
the Harvard Brain Tissue Resource Center obtained and processed by Marta Cortes-Canteli. 
AD patients were defined as being Braak stage 3-6, while ND controls were Braak stage 0-
2195 and matched with respect to age. Homogenates were prepared from the temporal pole 
region, which is strongly affected by Aβ plaques, tau pathology, and neuronal loss in 
AD196,197.  
Reducing western blot analysis of the soluble protein fraction from temporal pole tissue 
showed both uncleaved HK at 120 kDa and cleaved portions of the HK light chain (HKa) in 
AD and ND brains (Figure 5.7A, top panel). Levels of total HK (cleaved and uncleaved) 
normalized to actin were dramatically increased in AD brains (p = 0.012; Figure 5.7B) and 
correlated with Braak stage (r = 0.77, p <0.0001; Figure 5.7C). Brain HK accumulation was 
accompanied by HK cleavage, as seen through the appearance of cleaved HK light chain 
bands (Figure 5.7A), levels of which were significantly increased in Braak 6 AD brains 
compared to ND (p <0.05; Figure 5.7D) and correlated with Braak stage (r = 0.57, p = 0.008; 
Figure 5.7E). Cleaved HK levels in all AD vs. ND brains almost achieved significance (p = 
0.053), and would likely do so with more samples. Interestingly, the ND sample in lane 4 
(arrow) that had the highest level of cleaved HK fragments was at Braak stage 2, which is 
one stage prior to what is defined as clinical AD195. Together, these results suggest that HK 
accumulation and cleavage in the temporal pole are linked to disease onset and progression, 
and may be an early process in AD development. 
HK is an abundant plasma protein, and its increased presence in the AD brain could be 
explained by extravasation across a pathologically permeable BBB, known to occur in AD38. 
Brain levels of the plasma protein albumin also correlated with Braak stage (Figure 5.6A, 
third panel and 5.7F; r = 0.87, p <0.0001), supporting increased plasma protein 
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extravasation in AD. Although not widely reported, microglia have been shown to express 
albumin in vitro and in human AD brain tissue, and this expression is increased following 
microglial activation by Aβ42198. Thus, AD brains (which are characterized by Aβ42 
accumulation) would be expected to have higher levels of albumin independent of BBB 
permeability. Indeed, levels of other plasma proteins such as hemoglobin and fibrinogen are 
not increased in AD brains (Figure 5.7A, fourth and fifth panels), indicating that non-specific 








Figure 5.7. Increased HK accumulation and cleavage in AD patient brain. (A) Reducing 
Western blot analysis of the soluble fraction from the temporal pole in AD (Braak stage 3-6) 
and ND (Braak stage 0-2) brains. Purified uncleaved HK and cleaved HK (HKa) were loaded 
as controls. Blots were probed with antibodies against HK, actin, albumin, hemoglobin, and 
fibrinogen. A possible concern is that uncleaved HK may be absent in the first two ND 
samples because it has been fully cleaved and HKa bands further degraded. Non-reducing 
Western blot confirmed that the first two ND samples had very low levels of HK, and that 
cleaved HK was not being missed (not shown). (B) Levels of total HK (sum of uncleaved 
and both cleaved bands) normalized to actin were higher in AD vs. ND brains (p = 0.0123). 
(C) Total HK normalized to actin correlated with Braak stage (r = 0.77, p <0.0001). (D) 
Levels of cleaved HK normalized to actin were increased in Braak 6 AD patients compared 
to ND controls (p <0.05) and were trending higher in other AD groups. (E) Levels of cleaved 
HK normalized to actin correlated with Braak stage (r = 0.57, p = 0.008). (F) Levels of 




CHAPTER 6. DISCUSSION 
6.1. Overview 
In this thesis, I established the ability of Aβ to initiate prothrombotic and inflammatory 
processes via activation of the FXII-driven contact system, and provided evidence for these 
processes in AD patients and mouse models. I also defined the regions involved in Aβ42-
fibrinogen binding and elucidated the mechanism by which this interaction results in delayed 
fibrinolysis. Together, these results provide a basis for a novel hypothesis for the etiology of 
the vascular dysfunction that may play a key role in AD onset and progression. I will first 
discuss the results independently, then present the hypothesis derived from my combined 
findings.  
6.2. The Aβ-fibrin(ogen) interaction and Aβ’s role in clot susceptibility to fibrinolysis 
The Strickland laboratory has identified Aβ42 as a novel factor capable of modulating 
fibrin clot structure and stability. Results in Chapter 3 defined mechanisms by which fibrin 
clots formed in the presence of Aβ42 become more resistant to fibrinolysis and suggested 
mechanisms by which clot structure is altered. Structural and biochemical evidence supports 
the following hypothetical model (Figure 6.1) for the Aβ-fibrinogen interaction: The C-
terminal half of Aβ42 (residues 17-42) binds to fragment D of fibrinogen on the globular 
domain of its beta chain, near the b-hole (β366-414; Figures 3.1-3.3). Since the b-hole is 
involved in the lateral aggregation of fibrin protofibrils199, Aβ binding to this region may 
interfere with thickening of the fibrin network during clot formation, resulting in a thinner 
network (Figure 3.9). From the b-hole, Aβ stretches along the coiled-coil portion of fragment 
D, with the N-terminal portion of Aβ contacting the α-chain within this coiled-coil region. 
Since Aβ binds to fibrin fibers throughout the network (Figure 3.9) and not just to clumps as 
previously thought59, it could hinder the binding of plasminogen to fibrin at residues α148-
160160, thereby reducing network-wide plasmin generation and function.  
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Aβ may be introduced into fibrin clots in two ways, by intercalation into fibrin fibers during 
clot formation and by penetration into pre-formed clots. This is an important point, indicating 
that Aβ released from activated platelets126,200 can alter fibrin’s susceptibility to lysis after the 
clot has formed. The oligomeric state of Aβ42 required for delayed fibrinolysis has also been 
clarified: While Aβ oligomerization is necessary for delayed fibrinolysis (Figure 3.12), the 
formation of Aβ42 fibrils, which appear to induce clumping of the fibrin network (Figure 
3.12E,I), is not. Although we previously hypothesized that clumps mediate delayed 
fibrinolysis59, my current in vitro data indicate that two other mechanisms are responsible for 
the increased stability of Aβ42-influenced clots: thinning/tightening of the fibrin network and 






Figure 6.1. Model of the interaction between Aβ42 and fibrinogen fragment D. A ribbon 
diagram of fibrinogen fragment D (PDB 1FZA; light blue)132 with the 49 amino acid binding 
region (β366-414) for Aβ labeled in red and the β-chain loop that undergoes a shift in the 
presence of Aβ (β384-393) labeled in green. Alpha-chain residues implicated in 
plasminogen binding (α 148-160), which is inhibited in the presence of Aβ, are in gold. My 
combined results suggest that Aβ (hypothetical position represented in pink) binds to β366-
414 (red) with its C-terminal end, which results in a shift of the loop defined by β384-393 
(green). The N-terminal end of Aβ extends toward the coiled-coil region of fragment D, 
thereby blocking α148-160 (gold) necessary for plasminogen binding. The b-hole, centered 
around residues β397, β398201, and β432202 (teal), is implicated in lateral aggregation of 
fibrin protofibrils. Blocking of the b-hole by Aβ may contribute to the formation of thinner 




The interaction between Aβ and fibrin(ogen) in the cerebral circulation and brain 
parenchyma may therefore support increased thrombosis and fibrin accumulation, which are 
obstructive and proinflammatory, thereby contributing to AD pathology59,203. Indeed, vessel 
narrowing and occlusion caused by persistent fibrin(ogen) deposits co-localizing with Aβ 
were shown to contribute to impaired perfusion and reduced density of functional cortical 
microvessels in a mouse model of AD204. Furthermore, increased fibrin accumulation in the 
AD brain negatively affects synaptic health, and genetically decreasing fibrinogen in an AD 
mouse model ameliorates synaptic dysfunction and neuronal death205. The relevance of the 
Aβ-fibrinogen interaction to these processes is supported by studies demonstrating that 
inhibiting this interaction results in restored fibrinolysis in vitro and amelioration of pro-
thrombotic phenotype, microgliosis, and cognitive performance in a mouse model of AD206. 
6.3. Aβ is a prothrombotic factor via activation of FXII 
My results identify Aβ42 as a prothrombotic factor based not only on its ability to delay 
fibrinolysis (Chapter 3), but also on its ability to trigger thrombin generation via the intrinsic 
coagulation pathway (Chapter 4). Aβ42 oligomers triggered FXII-dependent activation of FXI, 
the first step of the intrinsic pathway, via a template mechanism (Figure 4.3), i.e. by binding 
and co-localizing contact activation factors. Aβ42-induced thrombin generation required the 
presence of phospholipids (Figure 4.1D), suggesting that while Aβ42 can serve as a surface 
for FXII-dependent FXI activation, phospholipid surfaces (necessary for efficient assembly of 
downstream coagulation cascade complexes) are required in order for thrombin generation 
to proceed.   
Aβ42-mediated, FXII-dependent FXI activation was previously not found122, likely due to 
the fact that amorphous aggregates of Aβ42 with the Dutch mutation (E22Q) were used. 
While Maas et al. found absolutely no FXI activation with Aβ42 Dutch amorphous 
aggregates, my results with Aβ42 Dutch oligomers showed low levels of FXII-dependent FXI 
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activation (Figure 4.3I). Thus, the assembly state of Aβ42 Dutch (amorphous aggregates vs. 
oligomers) plays an important role in determining its ability to induce FXI activation, a 
relationship also observed for Aβ42 (Figure 4.3G). Aβ42 oligomers were still much more 
potent in FXII-dependent FXI activation than Aβ42 Dutch oligomers, which may stem from 
differences in peptide charge (-2.7 for Aβ42 vs. -1.7 for Aβ42 Dutch at pH 7). A specific 
negative charge and/or the presence of glutamic acid at position 22 of Aβ42 therefore 
appears crucial for its interaction with and/or activation of FXII and FXI. Although the role of 
negative charge in Aβ’s ability to bind and activate FXII remains to be established, 
preliminary results suggest that the binding of Aβ42 to FXII is not negative charge-
dependent, but its ability to activate FXII is (not shown).  
Other physiological surfaces such as collagen207, polyphosphates180, and RNA181 have 
been shown to stimulate FXII-dependent FXI activation and thrombin generation. These 
surfaces are brought into contact with circulating FXII during vascular injury, cell death, and 
platelet activation. Aβ, however, is constantly present in the circulation, where it exists in a 
dynamic equilibrium with brain Aβ208. In AD, circulating Aβ may contribute to continuous low-
level FXII-dependent FXI activation, a hypothesis supported by decreased plasma levels of 
FXI zymogen and its inhibitor C1inh in AD patients compared to controls (Figure 4.5). 
Decreased levels of FXI and C1inh could reflect the clearance of the FXIa-C1inh complex 
following FXI activation209. Chronic FXI activation in AD could mediate the production of low 
“idling” levels of thrombin, which may contribute to the maintenance of a prothrombotic state 
in AD.  
The ability of circulating Aβ to trigger thrombin generation via FXII adds to its previously 
identified prothrombotic roles, including Aβ-mediated formation of fibrinolysis-resistant fibrin 
clots (See section 6.2) and Aβ-mediated platelet activation210-212. A combination of these 
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effects may participate in the establishment of the prothrombotic state observed in AD 
(Section 1.4). 
6.4. Aβ is a proinflammatory factor via activation of FXII 
FXII-dependent prekallikrein activation and subsequent HK cleavage by some Aβ40 and 
Aβ42 preparations has been shown in vitro121-123. In Chapter 5, I established that oligomeric 
Aβ42 is also capable of FXII-dependent prekallikrein activation and HK cleavage (Figure 
5.1), and showed for the first time increased FXII activation, kallikrein activity, and HK 
cleavage in AD patient circulation. HK cleavage correlated with early CSF biomarkers of AD 
(Figures 5.2, 5.3), suggesting that FXII-mediated kallikrein-kinin system activation is an early 
process in disease development that plateaus at more advanced stages. In collaboration 
with Dr. Zu-Lin Chen, I demonstrated that Aβ42 injected intravenously triggers kallikrein-
kinin system activation in mice, providing a mechanism for increased plasma HK cleavage in 
AD patients and mouse models (Figure 5.5). Previously, HK cleavage in AD patient plasma 
was not detected176, possibly due to the inclusion of polybrene in blood collection tubes in 
that study. Thus, chronic activation of the FXII-driven kallikrein-kinin system by Aβ42 in the 
AD circulation may induce constant low levels of bradykinin-mediated inflammatory 
processes, including increased BBB permeability, increased extravasation of plasma 
proteins in the brain parenchyma, and cytokine up-regulation106,213, all observed in AD24,38.  
My results suggest that activation of the FXII-driven kallikrein-kinin system by Aβ may 
contribute to AD pathology not only in the circulation, but also in the brain parenchyma. The 
co-localization of FXII with Aβ deposits in the cortex of AD mice (Figure 5.6A) and AD 
patients190 implicates Aβ-mediated FXII activation in the brain, supported by higher kallikrein 
activity in AD brain193 and by increased HK cleavage AD CSF214. My results indicate that HK 
accumulation and cleavage in the brains of AD mice (Figure 5.6C,D) and patients (Figure 
5.7) correlate with disease progression, suggesting that activation of the kallikrein-kinin 
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system may play a pathological role. It is unclear whether HK accumulation results from 
non-specific plasma protein extravasation through a more permeable BBB in AD38 or arises 
through other mechanisms, since not all plasma proteins tested were observed to 
accumulate in the brain with disease progression (Figure 5.6).  
6.5. Aβ levels in AD patients 
My hypothesis that Aβ42 contributes to thrombosis and inflammation by interacting with 
FXII requires the co-localization of Aβ42 with FXII at sufficient levels in the brain 
parenchyma and/or circulation. FXII is abundant in the circulation and has been found in the 
brain parenchyma190, thus being available in both compartments relevant to my data. Levels 
of Aβ42 in AD brain tissue are higher than in the ND brain215 and may begin to accumulate 
up to 20 years before disease onset216,217, allowing the Aβ-FXII interaction to be an early 
disease process. In plasma, reported concentrations of Aβ are in the picomolar range215, but 
these levels are likely to be underestimated due to binding of Aβ to plasma proteins and 
erythrocytes218. Indeed, techniques that measure total bound and unbound plasma Aβ have 
found concentrations in the nanomolar range218, similar to doses used to demonstrate a 
prothrombotic effect (Figure 4.1). Furthermore, much lower concentrations of Aβ than those 
required to demonstrate an acute effect in vitro may have significant effects on thrombosis 
and inflammation over the many years of AD development. 
If increased contact system activation observed in AD patient plasma is a result of Aβ42-
mediated FXII activation, levels of plasma Aβ42 would be expected to be elevated prior to 
AD onset and during AD development. While studies of high-risk populations for AD (Down 
syndrome patients, familial AD patients, and family members of AD patients) demonstrate 
increased plasma Aβ42 concentrations compared to controls219,220, the relationship between 
circulating Aβ42 levels and sporadic AD progression is less clear: cross-sectional studies of 
plasma Aβ42 have produced inconsistent results, while longitudinal studies have generally 
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found higher Aβ42 levels prior to and just at the onset of AD symptoms with a subsequent 
decrease219-221. This suggests that increases in plasma Aβ42 are early event in AD 
development, and supports Aβ42-mediated FXII activation as an early pathological process 
preceding the onset of symptoms.  
While elevated levels of Aβ42 prior to AD onset would directly facilitate contact system 
activation, its levels in more advanced disease stages do not necessarily need to be 
elevated, since changes to the vasculature that precede and accompany AD42 may create 
an environment that allows Aβ42 levels that cannot activate FXII in normal individuals to 
produce a pathological effect.  
6.6. A new role for circulating Aβ in the development of vascular dysfunction and AD 
The model illustrated in Figure 6.2 presents new mechanisms by which circulating Aβ 
may lead to vascular dysfunction and contribute to AD onset through FXII-dependent 
prothrombotic and inflammatory processes. Inflammation and coagulation are highly 
regulated systems that are typically activated in response to injury. In the proposed model, 
FXII activation by Aβ induces mild but chronic inflammation and thrombosis in the absence 
of injury, which, in the presence of subtle age- or disease-related inflammatory processes, 
can rise above threshold levels and contribute to AD onset and progression. 
Age- and genetics-associated decreases in the ability of clearance mechanisms to 
balance brain Aβ production9,222,223 may result in compensatory increased transport of Aβ 
across the BBB into the circulation. Elevated plasma Aβ levels, a risk factor for AD224-227, 
initiate pathological processes by triggering FXIl activation, leading to the generation of 
thrombin and bradykinin (Figure 6.2, Stage 1A). Alternatively, AD risk factors such as 
advanced age and vascular disease states may set the stage for AD development by 
producing changes in vessel wall biology34,42,47, inflammatory potential228, and platelet 
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activation state229. The resulting reduction in the thromboresistance of the vascular 
endothelium, increased activation of inflammatory pathways, and facilitated coagulation 
factor assembly on the surface of pre-activated platelets could allow normal levels of 
circulating Aβ to have prothrombotic effects (Figure 6.2, Stage 1B).  
At this point, thrombin and bradykinin induce small, localized changes to endothelial 
function and BBB permeability, further contributing to the prothrombotic and inflammatory 
environment99,100,104,106 (Figure 6.2, stage 2). Due to significant cross-talk between 
prothrombotic and inflammatory processes104,230-232, activation of inflammation and 
coagulation by Aβ is mutually reinforcing. Non-occlusive fibrin clot formation resulting from 
limited activation of the intrinsic coagulation and platelets may occur at these early levels of 
endothelial cell modification233 (Figure 6.2, Stage 3). Fibrin clots forming in the presence of 
Aβ would have increased resistance to fibrinolysis, enhancing their procoagulant and 
inflammatory potential. Initial non-occlusive thrombus formation aggravates endothelial 
dysfunction234, BBB permeability235 and inflammatory state236, and the resulting leakage of 
plasma components into the vessel wall leads to stiffening of the vessel and narrowing of 
the lumen, which decrease CBF and induce hypoperfusion28,115,237. Vessel stiffening 
combined with CBF disturbances also decrease the drainage of brain interstitial fluid along 
perivascular spaces, promoting Aβ accumulation in the brain238,239.  
Severe endothelial dysfunction combined with accumulating procoagulant factors can 
result in occlusive clot formation (Figure 6.2, Stage 4), which exacerbates hypoxic 
conditions and plasma protein extravasation into the brain parenchyma240. The combined 
effects of hypoxia and plasma protein leakage can induce astrocyte and microglial 
activation241-243.  Glial activation87 and CBF disruption244,245 are early events in AD 
development that can directly contribute to brain Aβ deposition, neurofibrillary tangle 





Figure 6.2. Model schematic. Stage1A. Increased transport of Aβ across the BBB due to 
age-related dysregulation of other clearance mechanisms results in elevated local levels of 
circulating Aβ, which lead to thrombin (Thr) and bradykinin (BK) generation through FXII-
driven contact system activation. Stage 1B. Alternatively, changes to vascular biology, 
inflammatory potential, and platelet activation state caused by aging and/or vascular risk 
factors create an environment where normal levels of Aβ trigger FXII activation. Stage 2. 
Thrombin and bradykinin induce increased BBB dysfunction, BBB permeability, and cytokine 
release via interactions with their receptors on endothelial cells. Stage 3. Once a threshold 
level of platelet- and intrinsic coagulation pathway activation is achieved, non-occlusive clots 
begin to form. These clots are more resistant to degradation due to Aβ-mediated 
stabilization of the fibrin network (blue mesh), resulting in prolonged proinflammatory and 
prothrombotic damage to the BBB. Plasma protein extravasation (blue shapes) induces 
vessel wall changes resulting in dysregulated clearance of Aβ through perivascular drainage 
and in decreased CBF. Stage 4. Occlusive clot formation exacerbates hypoxic conditions, 
BBB dysfunction, and extravasation of plasma components. Stage 3 and 4 changes can 
elicit vessel narrowing, decreased CBF, parenchymal Aβ deposition, tau phosphorylation, 
glial activation, and finally neuronal dysfunction.  
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6.7. Testing the model with existing evidence 
The model proposed above implies that modulating the functional levels of Aβ and/or 
members of the coagulation and kallikrein-kinin pathways in AD should ameliorate or 
exacerbate pathological processes initiated by contact system activation (i.e. BBB 
dysfunction, thrombosis, inflammation, and cognitive decline). Several lines of evidence 
indicate that this is indeed the case. In an AD mouse model, sequestration of Aβ by active 
immunization results in restoration of BBB integrity in aged mice and prevents BBB 
dysfunction when administered to young mice246. By contrast, intravenously injected Aβ 
increases BBB permeability in animal models247-249. Chronic cerebroventricular infusion of 
Aβ into rats induces bradykinin generation and subsequent AD-like pathology250, and 
pharmacological inhibition or genetic depletion of bradykinin receptors in AD mice results in 
reduced inflammation251, normalized CBF responses, and improved cognitive function252,253. 
Finally, plasma levels of C1 esterase inhibitor (which inhibits FXIIa, kallikrein, and FXIa) are 
decreased in prodromal AD254, suggesting that defects in the ability to control contact 
system activation may participate in disease onset and development, or that ongoing 
contact activation is depleting its levels. 
The end product of the intrinsic pathway of coagulation is thrombin, which induces 
inflammation and mediates the conversion of fibrinogen to fibrin. Long-term inhibition of 
thrombin activity in AD mouse models decreases cerebrovascular inflammation255, reduces 
Aβ accumulation76 and improves cognitive function77. Inhibiting the coagulation cascade at 
multiple points with warfarin improves cognitive function in AD patients73-75. Inducing 
persistent fibrin accumulation in an AD mouse model by inhibiting fibrinolysis exacerbates 
BBB permeability and neuroinflammation, while decreasing fibrinogen levels results in 
improved BBB function203 and cognitive performance59. Importantly, interfering with the Aβ-
fibrinogen interaction reduces thrombotic tendency and improves cognitive performance in 
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an AD mouse model206. Together, these results support a role for Aβ-induced activation of 
the contact system and for Aβ-mediated fibrin stability in eliciting vascular pathology and 
cognitive dysfunction in AD. 
Additional support for the model comes from striking similarities between the disease 
course implied by the described mechanisms and the pathological cascade of cerebral small 
vessel disease (SVD). SVD is associated with AD256,257, increases AD risk43, leads to AD 
pathology in animal models258 and humans259, and is found in the majority of AD 
patients30,237. SVD presents with degenerative changes in arteriolar vessel walls in the deep 
white and deep gray matter. These changes are accompanied by plasma component 
leakage into the vessel wall and perivascular tissue and can result in stroke and cognitive 
decline115. The trigger for the initiating event in SVD development, which is thought to be 
endothelial dysfunction102,115, remains elusive.  
Since the development of SVD (through endothelial dysfunction, BBB permeability, and 
plasma protein extravasation) mirrors the AD mechanism proposed in Figure 6.2, it is 
possible that SVD is a precursor to AD, and that the mechanisms for these disorders share 
a common trigger. Recent work has shown that in SVD, stalled erythrocytes accumulate in 
areas of future BBB breakdown and may thus initiate disease by an unknown mechanism233. 
Given that up to 50% of Aβ is bound to erythrocytes220, it is tempting to speculate that the 
elusive trigger for SVD onset is Aβ-mediated contact system activation, which may induce 
thrombosis and BBB dysfunction (Figure 6.2). This connection is supported by the 
observation of small non occlusive clots near stases233 and by correlations between plasma 
Aβ levels and pathological markers of SVD such as infarcts and white matter lesions260-262. 
Aβ-mediated contact system activation could thus contribute to localized edema, 
extravasation of plasma components, consequent stenosis of vessels, and hypoperfusion 
leading to SVD development and subsequent AD onset.  
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6.8. AD diagnosis and therapy  
A definitive AD diagnosis has traditionally been established upon post-mortem 
histological analysis of the brain, since a clinical diagnosis of cognitive decline is not 
necessarily specific to AD. Diagnostic challenges have hampered therapeutic efforts: 
Because clinically-measurable cognitive decline in AD is thought to manifest after significant 
pathological changes have occured263, treatment of symptomatic individuals may have 
limited efficacy (due to the advanced nature of disease processes).  
As research has focused on earlier stages of disease, it has become clear that 
pathological markers of AD, such as parenchymal Aβ accumulation, develop gradually and 
can precede cognitive and behavioral symptoms by 15-20 years2,183,216,217. Recent advances 
have made it possible to detect changes in Aβ homeostasis in living individuals using 
amyloid imaging techniques like Positron Emission Tomography with Pittsburgh compound 
and by measuring Aβ levels in the CSF. A combination of these and other methods now 
allow a diagnosis of AD to be established during life. However, the required techniques are 
expensive, invasive, and have limited availability. A more easily accessible biomarker with 
the ability to provide an AD diagnosis at early stages of disease would therefore be of great 
benefit to the field. My results indicate that plasma contact system activation has the 
potential to be one such biomarker. The value of contact system activation as an early 
indicator of disease is supported by the correlation between CSF Aβ42 levels and plasma 
HK cleavage as well as by contact system activation in pre-symptomatic individuals (Figure 
5.2D, red points).  
A definitive AD diagnosis during life is unfortunately of little help to the patient unless 
clinically meaningful treatment is available. Approved drugs for AD currently include 
acetylcholinesterase inhibitors and an NMDA receptor antagonist, both of which provide 
temporary relief by managing symptoms, but do not stop the progression of the disease. In 
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addition to therapeutic challenges stemming from late diagnosis, a possible reason for such 
limited success is that AD is a heterogeneous disease with potentially different driving 
mechanisms in different patients. Patients may therefore need therapy aimed at 
mechanisms specific to their disease to provide maximum efficacy. In this regard, monitoring 
the levels of plasma contact system activation could be used as a diagnostic tool to help 
identify AD patients with inflammatory and thrombotic disease mechanisms. If FXII 
activation is found to contribute to disease progression, identification of AD patients with this 
biochemical signature may pave the way for new therapies aimed at neutralizing FXIIa, such 
as anti-FXIIa antibody 3F7, which specifically blocks FXIIa activity and interferes with FXIIa-
driven bradykinin formation in plasma145.  
6.9. Future directions  
Role of Aβ-mediated prothrombotic and proinflammatory processes in AD. It will be 
important to determine whether activation of FXII-dependent intrinsic coagulation and 
plasma kallikrein-kinin pathways contributes to AD onset and development in vivo. The 
thrombotic potential, AD pathology, and cognitive performance of AD and littermate control 
mice should be assessed in the presence and absence of FXII. FXII depletion can be 
accomplished by crossing AD mice with FXII null mice, which are viable and have no 
obvious phenotype but are protected from thrombosis264. Thrombotic potential as measured 
by CAT144 or in vivo thrombosis assays59, BBB permeability, neuroinflammatory markers, 
and cognitive performance should be tested at different ages to determine if and through 
what mechanisms FXII is involved. The role of Aβ in this process may be defined by 
intravenous treatment of groups of mice with an anti-Aβ antibody. If FXII deficiency is 
protective in AD mouse models, the relative contributions of FXI-driven coagulation and 




Plasma contact system activation as a biomarker for AD. Increased plasma kallikrein 
activity and HK cleavage found in AD patients and mouse models (Figures 5.2-5.4) could be 
an exciting potential biomarker regardless of whether Aβ-mediated FXII activation is 
determined to be a causative mechanism in AD development. Increased kallikrein activity 
and HK cleavage will need to be validated in a larger cohort that includes individuals with 
familial and sporadic AD as well as individuals with other neurodegenerative diseases. 
Furthermore, blood collection protocols will need to be optimized to take advantage of the 
potential amplification of in vivo contact system activation observed in plasma from Group 1, 
and standardized to minimize differences in plasma activation during collection and storage. 
Most likely, HK cleavage would need to be used in conjunction with other disease markers 
to serve as a diagnostic tool for AD, since FXII activation and HK cleavage may also be 
features of unrelated disease states. Increased levels of FXIIa have been found in chronic 
conditions such as systemic amyloidosis122 and hyperlipidemia265 as well as following acute 
conditions such as ischemic stroke266 and myocardial infarction267. Increased cleavage of 
HK has been observed in chronic conditions like systemic lupus erythematosus268, certain 
cancers269, and during acute attacks in hereditary angioedema270. Evaluation of larger 
populations would help determine appropriate cut-off values for FXII activation and HK 
cleavage that may differentiate between AD and other disease states. For improved 
discrimination between AD and other disease states, plasma HK cleavage should also be 
tested as part of a panel of plasma components associated with AD as in 271-273. The 
development of an ELISA capable of distinguishing between cleaved and uncleaved HK 
would be beneficial to such studies.  
Role of contact system activation in the brain parenchyma. My results demonstrating 
increased levels of cleaved HK in AD patient and mouse model brain parenchyma strongly 
implicate contact system activation in brain tissue. The origin of contact activation proteins in 
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the AD brain is unclear. FXII and prekallikrein expression in normal brain tissue have been 
reported190,192,193, but HK mRNA was only detected under pathological conditions192,194. FXII, 
prekallikrein, and HK expression should be measured in AD mice and controls as a function 
of age and AD pathology. If local expression is not found, the mechanisms by which HK 
(and several other plasma proteins) extravasating across the BBB are retained in the AD 
brain while others are not will need to be investigated. The effect of HK cleavage in brain 
tissue on glial and neuronal health should also be investigated. While bradykinin released 
from HK could have proinflammatory and vasoactive effects, cleaved HK itself has anti-
angiogenic properties, and FXII and FXIIa are signaling molecules274. 
Epidemiological studies. AD risk should be assessed in individuals with deficiency in 
functional FXII, FXI, HK, and prekallikrein. Based on my results and model, these individuals 
would be expected to be protected from AD. By contrast, AD risk may be elevated in 
individuals with gain-of-function mutations in FXII or with decreased levels of functional C1 
esterase inhibitor.  
Aβ-mediated contact system activation and complement. Accumulating evidence 
implicates complement activation in AD275,276. Complement pathways can be activated by Aβ 
directly275 or by Aβ-induced FXIIa and kallikrein activity277. It would be interesting to 
determine the relative contributions of direct Aβ-mediated complement activation vs. Aβ-
induced, contact system-mediated complement activation in AD. This can be accomplished 
by blocking FXIIa and kallikrein activity in AD mice using ASOs, inhibitors, or genetics. Most 
studies have thus far focused on the role of complement in the brain parenchyma. The role 
of plasma complement activation in vascular pathology and AD development should be 
investigated. 
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Aβ40. An interesting consideration is the role of Aβ40 (which is more abundant in the 
circulation than Aβ42) in the activation of FXII-dependent processes. Preliminary results 
indicate that Aβ40 can also trigger FXII-dependent FXI activation and HK cleavage in 
plasma, although not as strongly as Aβ42. It is possible that the combined action of Aβ42 
and Aβ40 may be additive or even synergistic in triggering these pathways. 
6.10. Conclusion 
Cerebrovascular dysfunction and dysregulation of CBF are early processes in AD 
development, preceding Aβ plaque deposition, neuronal damage, and cognitive decline in 
AD28,244,278,279. Factors modulating CBF and vascular function could therefore have profound 
effects on disease onset and progression. In this thesis, I provided evidence that Aβ42 could 
be a driver of cerebrovascular dysfunction through activation of FXII, the primary trigger of 
both the intrinsic coagulation pathway and the kallikrein-kinin system, and through its 
interaction with fibrinogen.  
Because AD is a complex and multifactorial disease, it is unlikely that a single 
pathogenic mechanism will emerge. The ability to identify groups of patients with AD driven 
by specific mechanisms and to treat them accordingly would be a major advance in the field. 
If contact system activation is found to play a causative role in AD pathogenesis, targeting 
FXII, which is dispensable for hemostasis117, could provide novel therapeutic opportunities 
for individuals with elevated plasma HK cleavage.  
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